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INTRODUCTION 
COUMARIN 
 In Drug discovery, natural, synthetic and semisynthetic heterocyclic 
compounds play an important role in chemical biology. The heterocycles are 
mainly of the classes of alkaloids, flavones, isoflavones, chromans, chromones, 
coumarins and chromenes. It has been established that oxygen-containing 
heterocyclic compounds play an important role in designing new class of 
structural entities for medicinal applications.  Among oxygen heterocyclic 
compounds, coumarin (2H-chromen-2-one or 2H-1-benzopyran-2-one) and its 
derivatives are significant because of their wide spectrum of biological 
activities.
[1] 
 
2H-chromen-2-one or 2H-1-benzopyran-2-one 
 
The word coumarin derived from a French word coumarou. Coumarin is a 
large class of natural extract products, it considered to be the secondary metabolite 
in many higher plant species, particularly in leaves, seeds and roots
[2]
. They are 
found at high levels in some essential oils, particularly cinnamon bark oil (7,000 
ppm), cassia leaf oil (up to 87,300 ppm) and lavender oil
[3]
. Coumarin is also 
found in fruits (e.g. bilberry, cloudberry), green tea and other foods such as 
chicory. Most of the coumarins occur in higher plants, with the richest sources 
being Rutaceae and Umbelliferone
[4]
. It was been found in the tonka bean, was 
isolated in 1820.Coumarin plays an important role in regulation of plant growth 
and metabolites. According to different substituents in the overring, the coumarins 
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can be classified into simple coumarins, furano coumarins, pyrano coumarins and 
other coumarins, of which the furano coumarins and pyrano coumarins can be 
divided into linear type and angular type. Both natural and synthetic coumarin 
derivatives are considered to have a wide range of biological activity, such as anti-
diabetic
[5]
 , anti-inflammatory
[6]
, anticancer
[7,8]
, anti-coagulant
[9]
, anti-oxidant
[10]
, 
anti-HIV
[11] 
and anti-bacterial
[12,13]
, antiallergic, and antiproliferative activities
[14]
. 
Biological activity of coumarin has becoming an appealing point of studies owing 
to its different effects to diseases and less damage to normal cells
[15]
. Previous 
studies demonstrated that coumarin chalcone fibrates can down-regulate the total 
cholesterol (TC), phospholipids (PL), and triglycerides (TG), and regulate the 
levels of very low density lipoprotein(VLDL), low-density lipoprotein(LDL) and 
high density lipoprotein(HDL)
[16]
. Furthermore, 4-hydroxycoumarin dimers and 
Benzopyranocoumarin derivatives showed a powerful effect against HSV-1, 
HSV-2 and vaccinia virus at a nontoxic concentration
[17]
. Furthermore, the 
pharmacological properties as well as therapeutic applications of coumarins 
depend upon the pattern of substitution.  Apart from their therapeutical activities, 
it is also an important analytical agent. Regarding their high fluorescence ability, 
they are widely used as optical whitening agents, brighteners, laser dyes and also 
as fluorescent probes in biology and medicine
[18]
. Phytoalexins, a biosynthetic 
hydroxylated derivative of coumarins, which are produced in carrots will respond 
to fungal infection and can be assumed to have antifungal activity. General 
antimicrobial activity was provided in Woodruff (Galium odoratum) extracts.  
When coumarin moiety is fused with other moieties, a synergistic effect occurs in 
biological activities. Such compounds are exploited as important scaffolds for 
drug development.Some of the coumarin derivatives are already booming in the 
market.  Examples are given below in the figures 
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Most common Biological Activity and Pharmacological Activity of 
Coumarins: 
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A. ANTI-INFLAMMATORY ACTIVITY 
 Osteoarthritis, Alzheimer‟s disease, Cancers are associated with chronic 
inflammation. A Coumarin derivative IMMLG5521 has the anti-inflammatory 
activity of rat lung edema, which exhibits its effects by inhibiting the TNF-α 
expression, increasing the VCAM-1 and ICAM-1 expression level
[19]
. 
 
B. ANTICOAGULANT ACTIVITY 
 Vitamin K plays an important role in blood coagulation. The structure of 
warfarin is similar to vitamin K and it has anticoagulant activity which act as the 
vitamin K antagonist. Initially Warfarin was used as the poison to exterminate rats 
and then it has been the drug of anticoagulant for almost 60 years. Vitamin K can 
prompt the Vitamin K dependent coagulation factors (II, VII, IX, X), Warfarin 
exerts its anticoagulant activity by inhibiting the formation of vitamin K 
dependent coagulation factors (II, VII, IX, X) in the liver microsomal
[20]
. 
 
C. ANTICANCER ACTIVITY 
 Malignancies have become the biggest threat to human health. The 
anticancer activity seems to be the most important properties of coumarins. A 
coumarins derivative (RKS262) synthesised could inhibit ovarian cancer cells 
proliferation. 
 
D. ANTIDIABETIC ACTIVITY 
 Coumarins are secondary metabolites found widely in plants and used 
mainly in anticoagulant and antithrombic therapy. Over the past two 
decades,literature related to the effects of coumarins and their derivatives on 
diabetes and its complications are reported. The search for new coumarins against 
diabetes and its complications, either isolated from traditional medicine or 
chemically synthesised, has been constantly expanding. The cellular and 
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molecular mechanisms include protecting pancreatic beta cells from damage, 
improving abnormal insulin signalling, reducing oxidative stress/inflammation, 
activating AMP-activated protein kinase (AMPK), inhibiting α-amylase and α-
glucosidases
[5]
. 
 
DIABETES MELLITUS 
 Diabetes Mellitus is a metabolic disorder characterized by the presence of 
chronic hyperglycemia accompanied by greater or lesser impairment in the 
metabolism of carbohydrates, lipids and proteins. Etiology of Diabetes Mellitus 
includes defect in either insulin secretion or response or in both at some point in 
the course of disease. Mostly patients with diabetes mellitus have either Type 1 
diabetes (which is immune-mediated or idiopathic) Type 2 Diabetes Mellitus 
(formerly known as non-insulin dependent Diabetes Mellitus) are the most 
common forms of Diabetes Mellitus which is characterized by hyperglycemia, 
insulin resistance, and relative insulin deficiency
[21]
. 
 Type 2 Diabetes Mellitus results from interaction between genetic, 
environmental, behavioural factors
[22,23]
, and also includes  gestational hormonal 
environment, genetic defects, other infections, and even due to certain drugs. The 
worldwide prevalence of diabetes has continued to increase dramatically. 
Globally, as of 2011, an estimated 366 million people had Diabetes Mellitus, with 
Type 2 making up about 90% of the cases
[24,25]
. The number of people with Type 
2 Diabetes Mellitus is increasing in every country and 80% of the people living in 
low- and middle-income countries. The treatment goal of diabetic patients is to 
maintain near normal levels of glycemic control, in both fasting and post-prandial 
conditions. 
 
 Globally, an estimated 422 million adults were living with diabetes in 
2014, compared to 108 million in 1980. The percentage of deaths attributable to 
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high blood glucose or diabetes that occurs prior to age 70 were higher in low- and 
middle-income countries than in high-income countries(WHO,2016). The 
maximum number of diabetic patients was recorded in India followed by china 
and USA. If the current condition prevails and nothing much is done in future, 
then by the year 2030, number of individuals affected by diabetes in India would 
raise up to 79 million.  
 
CLASSIFICATION OF DIABETES MELLITUS 
 The classification of Diabetes Mellitus was based on etiological factors of 
the diseases. The old and confusing terms of insulin-dependent (IDDM) or non-
insulin-dependent (NIDDM) which were proposed by WHO in1980 and 1985 
have disappeared and the terms of new classification system identifies four types 
of diabetes mellitus: Type 1, Type 2, gestational diabetes and Monogenic diabetes. 
 
TYPE 1 DIABETES MELLITUS 
 Type 1 diabetes mellitus (juvenile diabetes) is characterized by beta cell 
destruction caused by an autoimmune process, usually leading to absolute insulin 
deficiency. Type 1 is usually characterized by the presence of anti–glutamic acid 
decarboxylase and islet cell or insulin antibodies which identify the autoimmune 
processes that lead to beta cell destruction. Eventually, all Type1 diabetic patients 
will require insulin therapy to maintain normoglycemia. 
 
TYPE 2 DIABETES MELLITUS 
 The relative defects in insulin secretion or in the exhibit intra-abdominal 
(visceral) obesity, which is closely related peripheral action of the hormone in the 
occurrence of Type 2 diabetes. This is the most common form of diabetes mellitus 
and is highly associated with family history of diabetes, older age, obesity and 
lack of exercise. Type 2 diabetes comprises 80% to 90% of all cases of Diabetes 
mellitus. Most individuals with Type 2 diabetes will be having insulin resistance, 
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hypertension and dyslipidemia (high triglyceride and low HDL-cholesterol levels; 
postprandial hyperlipidemia) often present in the individuals. It is more common 
in women, especially women with a history of gestational diabetes, and in Blacks, 
Hispanics and Native Americans. 
 
GESTATIONAL DIABETES MELLITUS (GDM) 
 Gestational diabetes mellitus is an operational classification (rather than a 
pathophysiologic condition) in which women who develop diabetes mellitus 
during gestation. Women who develop Type 1 diabetes mellitus during pregnancy 
and women with undiagnosed asymptomatic Type 2 diabetes mellitus that is 
discovered during pregnancy are classified as Gestational Diabetes Mellitus 
(GDM). In most women who develop GDM; the disorder has its onset in the third 
trimester of pregnancy. 
 
OTHER SPECIFIC TYPE (MONOGENIC DIABETES) 
 Types of diabetes mellitus of various known etiologies are grouped 
together to form the classifycation called “Other Specific Types”. This group 
includes persons with genetic defects of beta-cell function (this type of diabetes 
was formerly called MODY or maturity-onset diabetes in youth) or with defects of 
insulin action; persons with diseases of the exocrine pancreas, such as pancreatitis 
or cystic fibrosis; persons with dysfunction associated with other endocrinopathies 
(e.g. acromegaly); and persons with pancreatic dysfunction caused by drugs, 
chemicals or infections and they comprise less than 10% of Diabetes Mellitus 
cases.  
 
Importance of α-Amylase Enzyme in the Body 
In humans, the digestion of starch involves several stages. Initially, partial 
digestion by saliva results in the degradation of polymeric substrates into shorter 
oligomers. Later on in the gut these are further hydrolysed by pancreatic α-
amylase into maltose, maltotriose and small malto-oligosaccharides. The digestive 
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enzyme (α-amylase) is responsible for hydrolysing dietary starch (maltose), which 
breaks down into glucose prior to absorption. Inhibition of α-amylase can lead to 
reduction in post-prandial hyperglycemia in diabetic condition. 
 
Importance of α-Glucosidase Enzyme in the Body 
 α-glucosidase is a membrane bound enzyme located on the epithelium of 
the small intestine, catalysing the cleavage of disaccharides to form glucose. 
Inhibitors can retard the uptake of dietary carbohydrates and suppress post-
prandial hyperglycemia. Therefore, inhibition of α-glucosidase could be one of the 
most effective approaches to control diabetes. Glucosidases are not only essential 
to carbohydrates digestion, but also vital for the processing of glycoprotein and 
glycolipids. This enzyme is a target for antiviral agents that interfere with the 
formation of essential glycoproteins required in viral assembly, secretion and 
infection. Glucosidase are also involved in a variety of metabolic disorders and 
carcinogenesis
[26,27]
. 
 
ENZYMES
[28] 
 Enzymes are proteins, macromolecules they catalyse the chemical 
reactions in biological systems. They are specific in nature. 
There are three different types of enzymes in human body, they are. 
 
1) Metabolic enzymes  
 They are the spark of life, the energy of life, and the vitality of life. In 
human body every biochemical reactions that occurs are catalyst and regulated by 
enzymes only and making them essential to cellular functions and health. 
 
 
2) Food enzymes  
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 By consumption of supplemental enzyme products and through the raw 
foods we eat these food enzymes get into the body. Raw foods are the source of 
digestive enzymes when ingested. However raw food manifest only enough 
enzymes to digest the particular food, not enough to be stored in the body for the 
later use. 
 
3) Digestive enzymes  
 Helps in digesting the food and the nutrients in the food are delivered to 
different parts of the body. The most important digestive enzymes are a) Proteases 
(split proteins into their monomers, the amino acids), b) Lipases (split fat into free 
acids and glycerol molecules),  
c) Carbohydrases (split carbohydrates such as starch and sugar into sample sugars 
such as glucose) and d) Nucleases (split nucleic acid into nucleotides) 
In which α-amylase is one of the digestive enzyme since it begins its 
process by digesting the starch and breaks them into smaller pieces with two or 
three glucose units.  
 
α – Amylase[29] 
 α- amylase is found in the saliva, pancreatic secretions, and in the 
gastrointestinal tract. It severs an obvious role in polysaccharide digestion. α-
amylase determination has been recognized as an important role for the diagnosis 
of diabetes for many years because elevated levels of the enzyme are associated 
with liver and pancreatic disorders. 
 
 The structure of starch consists of glucose polymers linked by α-1,4 and α-
1,6 glycosidic bonds. α-amylase is an enzyme that catalyses the hydrolysis of 
starch into sugar. Amylase hydrolyse internal α-1,4- glucosidic linkage in starch. 
Largely at random, to produce dextrins and  disaccharides. 
Strach (insoluble) 
 
 α-amylase 
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Dextrins   
      α-amylase 
    
Disaccharides 
                       α – glucosidase 
Monosaccharide glucose 
 
 
Readily absorbed in GIT 
 
 
Blood stream glucose level increases 
 
 First α-amylase degrade starch into dextrins and then to maltose by 
hydrolysing α-1,4 glucan bonds. In digestion, the primary role of α- amylase is to 
perform the first reaction of this process, generating dextrins that are subsequently 
hydrolysed by other enzymes. This will comes under the classification of 
carbohydrates. 
Starch 
 Starch is the most important dietary source for humans. High content of 
starch is found in cereals, roots, tubers etc. Starch is a homopolymer composed of 
D- Glucose units held by α-glycosidic bonds. It is known as glucosan or glucan. 
Starch consists of two polysaccharide components – water soluble amylaseand a 
water insoluble amylopectin. Chemically amylase is a long unbranched chain with 
200- 1000 D-glucose units held by α-1,4- glycosidic linkages. 
 
 
 Amylopectin, on the other hand, is a branched chain with α-1,6 glucosidic 
linkages at the branching points and α-1,4 linkage in the other place. Amylopectin 
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molecule, which is composed of a few thousand glucose units, looks like a 
branched tree with 20-30 glucose units/ branch. 
Enzyme inhibitors
[30] 
 The molecules which bind to enzymes and decrease their activity are 
termed as Enzyme inhibitors. Many drugs are enzyme inhibitors, since it can 
block an enzyme activity and correct a metabolic imbalance. Some of the enzyme 
inhibitors are also herbicides and pesticides. Not all molecules that bind to 
enzymes are inhibitors. There are also enzyme activators that bind to the enzyme 
it enhance the enzymatic activity, while enzymes substrates bind and are 
converted to products in the normal catalytic cycle of the enzyme. 
 The binding of an inhibitor can stop a substrate from entering the 
enzymes‟s active site and/ or hinder the enzyme from catalysing its reaction. In 
the past the only way to discover these new inhibitors was by trial and error. This 
brute force approach is still successful and has even been extended by 
combinatorial chemistry approaches that quickly produce large number of novel 
compounds and high- throughput screening technology to rapidly screen these 
huge chemical libraries for useful inhibitors. 
α-Amylase Inhibitors[31] 
 The activity of α-amylase is reported to be inhibited incase of diabetes. 
Therefore these α- amylase inhibitors are acting as antidiabetic drugs that work by 
preventing the digestion of carbohydrates. 
 
 
 
 
The inhibition of α- amylase is by., 
 Metal chelators, organic acids and heavy inorganic metal ions: 
Introduction 
 
 
 
 
 
Department of Pharmaceutical Chemistry 12 
 All metal chelators are strong inhibitors of amylase as they are 
metalloenzymes. Eg. EDTA, of the organic acids, citric acid and oxalic 
acid is found to be the most potent inhibitor of amylase. Heavy metal ions 
such as Al
3+
, Fe
2+
, and Hg
2+
 are known to inhibit amylase at higher 
concentration. 
 Crude plant extracts: A number of crude plants extracts have been 
reported to have α- amylase inhibitory activity by many researchers. Some 
of the plant species like Murraya koenigii and Ocimum  tenuiflorum 
extracts of which are reported to have appreciable α- amylase inhibitory 
activity. 
 Pure natural products: A synthetic pseudotetrasaccharide, Acarbose 
originally isolated from microorganisms, is an established inhibitor of both 
α- amylase and α- glucosidase. 
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ACARBOSE 
 
            
               α- amylase             α- amylase      α- glucosidase 
    Starch             Dextrins                           Maltose                Glucose 
 
Pharmaceutical significance of  α- amylase inhibitors: 
 α- amylase inhibitors inhibit the digestion and the production of glucose 
from complex polysaccharides. These inhibitors have the potential to supress post 
prandial blood glucose level in diabetic patients. Acarbose which lower blood 
glucose by inhibiting α- amylase and α- glucosidases is currently used as an 
antidiabetic drug. 
 Tendamistat (produced by stretomyces tendae and stretomyces lividans) is 
an extracellular polypeptide containing 74 amino acids, which showed significant 
biological activity similar to α- amylase inhibitor and it has been shown to have 
significant application in the treatment of diabetes mellitus. Due to its resistance 
against most hydrolytic enzymes, tendamistat would be orally available for the 
treatment of diabetes mellitus. Adiposin-1 (isolated from Streptomyces calvus) 
inhibits human α- amylase, is another example of potential antidiabetic 
compounds obtained from microbes. 
 
Drug discovery
[32-35] 
 Drug discovery and development is a research process where, a new 
chemical entity (synthetic or natural) is recognized and developed by designing 
and screening against a proper biochemical target. It is an innovative science 
where knowledge and technologies are incorporated to convert a chemical moiety 
into useful therapeutic drug. This system approaches the discovery in a trial and 
error method. 
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 Drug discovery is an expensive and time consuming process. In this area a 
new drug may be developed or existing drugs may be modified with 
 Same therapeutic activity with lesser toxic effects 
 More therapeutic activity with lesser toxic effects 
 Drug discovery involves different phases and is a team effort which 
requires constant participation and heartful in, designing and experimental 
findings, development and marketing disciplines. 
 
Drug design 
 Drug designing is otherwise known as rational drug design and it is a 
method of finding new medication based on the biological receptors and target 
molecules. It is also a process of developing a drug with high therapeutic index 
and specific action. It involves the identification of a compound that displays a 
biological profile and ends when the biological profile and chemical synthesis of 
the new chemical entity are optimized. Drug design includes the design of small 
molecules, which are having similarity in shape and charge to the biomolecular 
target to which the drugs will bind. Here drug is an organic small molecule which 
will either activate or inhibit the function of a protein. 
 
Aim of drug design 
 To improve potency 
 To modify specificity of action 
 To improve duration of action 
 To reduce toxicity 
 To effect ease of application or administration or handling 
 To improve  stability 
 To reduce cost of production 
 Modern method of drug designing is done with the aid of computers and 
hence, the process is known as Computer Assisted/ Aided Drug Design (CADD). 
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It uses computational chemistry to study about the drugs and related biologically 
active molecules. The major aim is to find whether the given molecule bind to the 
target and causes pharmacological action or not. 
 
The basic steps involved in CADD are: 
 Hit identification using virtual screening 
 Hit-to-lead optimization and selectivity 
 Lead optimization of other pharmaceutical properties maintaining  affinity 
Drug design help to explain the following: 
 The effects of biological compounds on the basis of chemical 
 properties of the molecule involved. 
 Different processes by which the drugs shows their  pharmacological 
 effects. 
 How the drug react with the sites to produce a particular 
 pharmacological response 
 How the drugs are detoxicated , metabolized or eliminated by 
 organism 
 The relationship between chemical structure and biological  response. 
Types of Drug Design 
 Ligand based drug design 
 Structure based drug design 
 De novo design 
 Homology modelling 
 
 
Ligand Based Drug Design (LBDD) 
 Ligand based method is used to know about inhibitors for the target 
receptors, in the absence of the structural information of the target. It is also 
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known as indirect drug design. By using structural or topological similarity or 
pharmacophoric similarity properties, biologically lead molecule is detected. 
There are several criterias for similarity comparisons such as structure as well as 
shape of individual fragment or electrostatic properties of the molecule. The 
generated lead molecules are ranked based on their similarity score or obtained by 
using different methods or algorithms. 
 
Structure Based Drug Design (SBDD) 
 SBDD is used to create a homology model of target when the experimental 
structure is unavailable. It is also known as direct drug design. The ultimate goal 
of structure-based drug design is to develop a simple, robust process that starts 
with ahigh-resolution crystal structure of a validated biological macromolecular 
target and finally generates an easily synthesised, high-affinity small molecule 
with desirable pharmacological properties. It depends on the knowledge of 3D 
structure of the biological target that is obtained via methods such as X-ray 
crystallography, NMR spectroscopy or homology modelling. With the three 
dimensional structure of the target obtained from X-ray crystallography or NMR 
spectroscopy, one can begin the search for a ligand whose orientation and 
conformation is complimentary to the receptor structure. 
 
Typically, the process involves 
 Obtaining the structure of the target protein 
 Identification of active site 
 Virtual  screening of a small molecule database 
 Identification of potential ligands based on a chosen scoring 
 function. 
 
Drug Discovery methods
[36,37] 
1. Real screening 
2. Virtual screening 
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Real screening 
 It include methods like high-through screening (HTS) which can 
experimentally check the activity of hundreds or thousands of compounds against 
the particular target limited time. Although, it is highly expensive, it provides real 
results which can be used for drug discovery. 
 
Virtual screening 
 Virtual screening is a process for searching ligands i.e.; small biologically 
active molecules by means of computer assisted technique on the basis of 
biological structure. The crucial aim of virtual screening is the reduction of the 
enormous small organic molecules, to synthesize and screen against a particular 
target protein, to a manageable number of the compound as drug candidate. 
Steps involved in drug design
[35] 
 The drug design process may be categorized into following four distinct 
stages: 
 
 Selection and identification of the target 
 Drug discovery process begins with the identification of a possible 
therapeutic target. The selected drug target must be a key molecule involved in a 
specific metabolic or cell signalling pathway that is known or believed to be 
related to a particular disease state. 
 
Important drug targets include: 
 Enzymes (inhibitor- reversible or irreversible) 
 Receptors (agonist or antagonist) 
 Nucleic acid intercalators or modifiers 
 Ion channels (blockers or openers) 
 Transporters (uptake inhibitors) 
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 The 3D structure of the protein target is usually obtained by X-ray 
crystallography (crystal structures of different macromolecules are available from 
the research collaborator for structural bioinformatics (RCBS) protein database), 
Nuclear Magnetic Resonance (NMR) or homology modelling from a previously 
determined structure. 
 
 Search for lead ( lead identification) 
 Lead structures are ligands which are selected from a series of related 
compounds that exhibit suboptimal target binding affinity. After lead selection, 
they are tested for their activity towards a desired drug target. 
 
a) De novo molecular design 
 This approach is used to design new structures by sequentially adding 
molecular fragments to a growing or by adding functionality to an 
appropriately sized molecular scaffold. 
 
b) Database search methods 
 The lead molecule can be selected by screening structures found in various 
chemical database which contain an ocean of scaffolds. 
 
c) Combinatorial methods 
 Combinatorial chemistry helps to create a large library of varied molecular 
structures by using a single scaffold and diverse array of  reactants. 
 
 
 
 Lead optimization 
 Lead optimization is a process in which lead compounds are altered to 
make them more effective and safer i.e., to achieve maximum affinity to the target 
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with improved bioavailability and low toxicity. By effective combination of two 
or more active moieties or by elimination or substitution of various groups, the 
properties of the lead compound can be modified. 
 
Drug Likeness
[38,39] 
 Drug likeness may be defined as a complex balance of various molecular 
properties and structural features which in turn determine whether a particular 
molecule is similar to the known drugs. 
 The concepts of drug likeness play an essential role in the transformation 
of a clinical candidate to a marketed product. These likeness properties can be 
found out from the molecular structure before synthesizing and testing a 
substance. 
 A drug should have both water and fat solubility because an orally 
administered drug has to go through the intestinal lining, carried in aqueous blood 
and penetrate the lipid cellular membrane to reach the inside of the cell. Partition 
coefficient known as log P is used to estimate solubility. 
 It has to be sufficiently water soluble because the drug is transported in 
aqueous media like blood and intercellular fluid. Solubility in water can be 
estimated from the number of hydrogen bond donors vs. alkyl side chain in the 
molecule. 
 Low water solubility leads to slow absorption and action. Too many 
hydrogen bond donors leads to low fat solubility, so that the drug cannot penetrate 
the cell wall reach the inside of the cell. 
 Smaller molecular weight is better, because diffusion is directly affected. 
80% of traded drugs have molecular weights under 450 Dalton. Using a drug 
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likeness index leads to rejecting nonviable lead compounds before they are even 
synthesized. One of the traditional rules of thumb is Lipinski‟s Rule of five. 
 
Lipinski’s Rule of five 
 It is a rule of thumb which evaluates drug likeness and it determine 
whether a chemical compound can make an orally active drug in human. It may 
have specific pharmaceutical or biological properties that would make it a likely 
orally active drugs in humans. Most medications are relatively small lipophilic 
molecule. Based on this Christopher A Lipinski formulated this rule. The rule is 
important for drug development where a pharmacological active lead structure is 
optimized stepwise for increased activity and selectively as well as drug like 
properties as described by Lipinski‟s rule. 
 
The Rule: 
Lipinski‟s rule of five states that, in general, an orally active drug has: 
1) Not more than 5 hydrogen bond donors (OH & NH group) 
2) Not more than 10 hydrogen bond acceptors (N & O groups) 
3) Molecular weight under 500g 
4) Partition co efficient log P less than 5 
5) Number of violations less than 5 
 
 It is to be noted that all the numbers are multiples of five, which is the 
basis for the rules name. 
Improvements 
 Partition coefficient Log P is -0.4 to 15.6 range 
 Molecular refractivity from 40-130 
 Molecular weight from 160-480 
 
 No. of heavy atoms from 20 to 70 
 Polar surface area must not be greater than 140 Å  
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 Once the lead is being optimized, it is taken for the docking studies. 
 
DOCKING
[40,41]
  
 Docking is a method which predicts the preferred orientation of one 
molecule to a second when bound to each other to form a stable complex. 
Preferred orientation helps to predict the strength of association of or binding 
affinity between two molecules. The associations with biological molecules such 
as proteins, nucleic acids, carbohydrates and lipids play an important role in signal 
transduction i.e. agonism or antagonism. So docking is a useful tool for predicting 
both the strength and type of signal produced.  
 Molecular docking may be defined as an optimization program, which 
would describe the „best-fit‟ orientation of a ligand that binds to a particular 
protein of interest. The focus of molecular docking is to computationally stimulate 
the molecular recognition process. The aim of molecular docking is to achieve an 
optimized conformation for both the protein and ligand and relative orientation 
between protein and ligand such that the free energy of the overall system is 
minimized.  
A molecular docking calculation consists of the following steps:  
 Optimization of the ligand geometry, calculation of pH-dependent  partial 
 charges, and identification of rotatable bonds.  
 Calculation of electrostatic properties of the protein of interest and 
 defining the ligand –binding region.  
 Calculation of ligand-protein interaction by a scoring function that 
includes terms and equations that describe the intermolecular energies.  
 Docking produces plausible candidate structures. These candidates must 
be ranked by using scoring functions and to identify structures that are most likely 
to occur in nature.  
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Rigid-body docking and flexible docking  
 If the bond angles, torsion angles and bond lengths of the components are 
not modified at any stage of complex generation, then they are known as rigid 
body docking. A rigid-body docking is sufficiently good for most docking, when 
substantial change occurs within the components at rigid-body docking. Docking 
procedures which permit flexible docking procedures or conformational change, 
must intelligently select small subset of possible conformational changes for 
consideration.  
 
Mechanics of docking 
 To perform a docking screen, the first requirement is a structure of 
interested protein. Usually the structure has been measured using a biophysical 
technique such as X-ray crystallography or NMR spectroscopy. The protein 
structure and a database of potential ligands serve as inputs to a docking program. 
The success of a docking program is based on two components:  
 Search algorithm  
 The search space includes all possible orientations and conformations of 
the protein paired with ligand. With present computing resources, it is impossible 
to exhaustively explore the search space; which involves enumerating all possible 
distortions of each molecule (molecules are dynamic and exist in an ensemble of 
conformational states) and all possible rotational and translational orientations of 
ligand relative to the protein at a given level of granularity. Most docking 
programs account for a flexible ligand, and several are attempting to model a 
flexible protein receptor. Each “snapshot” of the pair is referred to as a pose.  
 There are many conditions for sampling the search space. Here are some 
examples:  
 Use a coarse-grained molecular dynamics simulation to propose 
energetically reasonable poses stimulation. (direct search-simplex method; 
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gradient-based search-steepest descent, Fletcher-Reeves method, Newton-
Raphson method; least square methods-Marquardt method)  
 Simulated annealing (Monte Carlo search of the parameter space)  
 Use a “linear combination” multiple structures determined for the same 
protein to emulate receptor flexibility  
 Use a genetic algorithm to “evolve” new poses that are successively more 
fragment-based construction.  
 
 Scoring function 
 The scoring function takes a pose as input, returns a number indicating the 
likelihood that the pose represents the favorable binding interaction.  
 Most scoring functions are physics based molecular mechanics force fields 
that estimate the energy of the pose; a low (negative) energy indicates a stable 
system and thus likely for a binding interaction. It is an alternative approach to 
derive a statistical potential for interactions from a large database of protein-
ligand complexes, such as the Protein Data Bank. This evaluates the fit of the pose 
according to this inferred potential.  
There are a large number of structures from X-ray crystallography for complexes 
between proteins and high affinity ligands. It is comparatively fewer for low 
affinity ligands as the later complexes tend to be less stable and therefore more 
difficult to crystallize. Scoring function trained with this data can dock hits 
(ligands predicted to bind to the protein and actually does not, when placed 
together in a test tube).  
 
Various softwares used for docking studies are:  
 AutoDock 4.2  
 Gold  
 Vega  
Introduction 
 
 
 
 
 
Department of Pharmaceutical Chemistry 24 
 Glide  
 Flexidock  
 Flex  
 Fred 
 Hint etc  
Autodock 4.2  
 
 Autodock is a suite of automated docking tools. It is designed to predict 
how small molecules, such as substrates or drug candidates, bind to a receptor of 
known 3D structure. Autodock uses Monte Carlo method and simulated annealing 
in combination with genetic algorithm for building the possible conformations. 
The genetic algorithm is used for global optimization. Autodock works in Linux 
platform. Cygwin is used as a user friendly interface. The local search method is 
energy minimization and Amber “force field” model helps in the evaluation of 
binding positions compatible with several scoring functions based on the free 
energy. The atomic affinity grids can be visualized. This is helpful to guide 
organic synthetic chemists to design better binders.  
 
Autodock consists of two main programs:  
1. AutoGrid pre-calculates the grids. 
2. AutoDock perform the docking of the ligand to a set of grids 
 describing the target protein.  
 It also has got capabilities to visualize atomic affinity grids and its 
graphical user interface, thus to support the analysis of docking results. It has an 
advantage of getting free academic license, at the same time parallel computation 
is not supported.  
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 The aim of the present work was to synthesize new pyrazole and isoxazole 
derivatives containing coumarin moiety in order to explore the extent of their α- 
amylase inhibitory activity. The compounds were designed by in silico method 
using α- amylase as the target molecule.   
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LITERATURE REVIEW 
COUMARINS 
A. Coumarin as Antidiabetic agents 
 
 Deepthikini and Manjunathghate et al., (2010),  performed a  Synthesis  
on the series of 3-[5
I
-Methyl – 2I aryl- 3I – (thiazol-2II- yl amino) thiazolidin – 4I-
one] coumarin and screened for oral hypoglycemic activity in chemically induced 
Type 2 diabetic rates, to prove their promising activity
[42]
. 
O O
N
S
NH
N
SO
CH3
R
R- H, 4-CH3, 4-Cl, 4-OH,
5,6-Benzo, 4-F, 4-NO2, 2-Cl, 2-Br, 
4-Br
 
 Anchal Verma et al., (2013), Performed an isolation of Scopoletin, a 
derivative of coumarins, 7-Hydroxy-6-methoxycoumarin was evaluated for the 
hypoglycemic and hypolipidemic activity in Wistar rats in streptozotocin induced 
diabetic rats
[43]
. 
 
O OOH
H3CO  
 Vahan G. Prajapati et al., (2013), Performed an synthesis of Guanidine 
derivatives which is combined with  2H-chromene moiety and antidiabetic activity 
has been performed for guanidine derivatives which shows a promising 
activity
[44]
. 
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Cl
NH NH O O O
NH
NH O
  
 Nagwa M. M. Shalaby et al., (2014), performed an isolation of 
furanocoumarins and  in vitro evaluation of the antidiabetic activity of crude 
extract showed the most potent inhibiting power
[45]
. 
 
   
O OO
R1
R2
R1-H,OCH3,H
R2-H,H,OCH3
 
 
 Andy Ramu and Veluchamy vijayakumar et al., (2016), Done a 
isolation of 7- methoxy coumarin from the bark of marine plant Rhizophora 
mucronata and screened for Invitro antidiabetic activity in chemically induced 
Wistar rats and male swis albino mice, which proved to coumarins having 
antidiabetic activity
[46]
. 
   O OO
CH3
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2. Coumarins with antimicrobial activity 
a) Coumarins as antitubercular agents 
 Jeyachandran et al., (2012), performed a synthesis on the  series of 4-
aryl/ alkyl sulfonyl methyl coumarins and screened for in vitro antitubercular 
activity against Mycobacterium tuberculosis H37Rv (MTB) to prove their 
potential activity
[47]
. 
 
O
S
R
1
R
2
R
O
O
O
R-phenyl;p-Methylphenyl,p-chlorophenyl; 
2-benzoxazolyl; 2-benzimidazolyl; cyclohexyl
R1- H; OCH
3
R2- H; OCH
3
 
 
 Kawate et al.,(2013), investigated a series of coumarin derivatives 
conjugated with isoniazid and pyrazole moieties and evaluated their anti-TB 
activity against MTB H37Rv Using Resazurin MIC assay. The synthesised 
Compounds containing a4-fluoro group at C-3 phenyl ring of pyrazole ring 
showed promising antimycobacterial potential
[48]
. 
 
N
N
N
O
O
O
F
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b) Coumarins with Antibacterial activity 
 Kulkarni et al., (2010), were synthesized some 4-azidomethyl-7-
methylcoumarin-6-sulphonamides which showed very potent antibacterial 
activity
[49]
. 
 O OCH3
S
NH
N2
O
O
R
R-H,3-CH
3,
4-CH
3
,3,4-CH
3
,2,5-CH
3,
2-OCH
3
,4-OCH
3
,4-Cl,4-Br,3-Cl
 
 Lin et al., (2012), tested acyl coumarins, 4-hydroxy, and 7-Hydroxyl 
coumarins and coumaric amide dimers against B. subtilis, S. aureus,  
E. coli and Pseudomonas aeruginosa and Penicillin G potassium salt was used as 
a reference drug. The Compounds was the most potent compound out of the tested 
compounds against Bacillus subtilis
[50]
 
O
O
O
CH3
CH3
NH
O
 
c) Coumarin as Antifungal agents 
 Mohamed et al., (2012), screened some 8-ethoxycoumarins for their in-
vitro antimicrobial activities against two Gram negative Bordetella bronchiseptica 
and E. coli and four Gram positive Bacillus pumilus, B. subtilis,S. aureus and 
Staphylococcus epidermidis pathogenic bacteria and two fungi Candida albicans 
and Saccharomyces cervesia. Compound resulted in wide spectrum antimicrobial 
activity against all tested bacteria and fungi compared to ampicillin (25μg/ml) and 
mycostatin (25μg/ml) [51]. 
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O
O
O
CH3
N
H
S
NC
N
NH
H3CO
 
 Kudale et al., (2012), investigated a series of 3-(4-(4-(substituted 
phenyl)prop-1-ene-3-one) phenylimino) methyl)-4-chloro-2H-chromen-2-ones in-
vitro against gram positive bacteria, S. aureus, B. subtilis and  
S. epidermis and gram negative bacteria, E. coli, S. typhi and  
P. aeruginosa and the antifungal activity was evaluated against A. niger and 
Clostridium albicans using amoxicillin and fluconazole as standard drugs for 
antibacterial and antifungal activities respectively. Compound was to be most 
active against all the tested organisms
[52]
. 
O O
Cl
N
O
Cl 
 
3. Coumarin as Antiviral agents 
 Trivedi et al., (2007), investigated a newly synthesized coumarinyl 
chalcone derivatives which were evaluated for their antiviral activity
[49]
. And 
shows potent activity
[53]
. 
 
O O
OH
R4
R3
R2
R1 O
R
R=H,4-OH,4-OCH3,3-OC6H5,2-NO2
R1=CH3,CH3,CH3,CH3,CH3
R2=H,H,H,H,H
R3=H,H,H,H,H
R4=CH(CH3)2,CH(CH3)2,CH(CH3)2,CH(CH3)2,
CH(CH3)2
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4. Coumarins with Anti–inflammatory, Analgesic activity and 
 Antipyretic agents 
 
 Bylov et al., (1999), evaluated a series of N-aryl substituted  
2-imino -2H-1-benzopyran-3-carboxamides and 2-oxo-2H-1-benzopyran-3-
carboxamides for anti-inflammatory activity in albino rats. The results were found 
to be comparable with piroxicam taken as the reference drug
[54]
.  
 
O
NH
NH
O
R
R=2-COOCH
3
,4-COOCH
3
O O
NH
O
O OH
R
R=H,5-OCH
3
,5-NO
2,
5-Cl
 
 
 Kalluraya et al., (2001), were synthesised 6-substituted-3-[4-(3-
substituted pyrazolidine)hydrazine-4-thiazolyl] coumarins which exhibited 
analgesic activity
[55]
. 
 
O
O
NH
OH
R
R=6-CH3,7-CH3,5,6-Benzo,6-Cl,7-Cl,6-OCH3
 
 Ghate and Kulkarni et al., (2005), have reported the synthesis of 4-(5’-
acetyl-6’-hydroxy-3’-methyl benzofuran-2’-yl) coumarin and 6-acetyl-3,7-
dimethyl-2-(coumarin-4’-yl)furo[3,2-g]chromen-5-one and established their good 
anti inflammatory and analgesic activity
[56]
. 
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O
O
CH3
O
O
O
O
CH3
R
R=6-CH
3
,7-CH
3
,5,6-Benzo,7,8-benzo,
6-OCH
3
 
 Khode et al., (2009), screened a series of 5-(substituted)aryl-3-
(3coumarinyl)-1-phenyl-2-pyrazolines for their in vivo anti-inflammatory and 
analgesic activities. Some of the compounds exhibited significant analgesic 
activity and antipyretic activity with minimum ulcerogenic index
[57]
. 
 
O O
N N
CH3CH3
 
 
 Bansal et al., (2009), were synthesised 7-methoxy-4-(3’-substituted 2’-
oxo-1’,2’,3’,5’-oxathiazol-4’-yl) coumarins which showed anti inflammatory 
activity
[58]
. 
O O
NHN
OS
O
H3CO
R
R=H,NO
2
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5. Coumarin as Vasorelaxant agents 
 Manuel Campose Toimil et al., (2002), were synthesised a new series 
coumarins and furocoumarins and evaluated their Vasorelaxant activity
[59]
. 
 
 
O
O
O
CH3 OH
R
R=H,OCH
3
,OCH
3
CH
3
 
6. Coumarins with Anticancer activity 
 Bhattacharya et al., (2009), were synthesized 4-methyl-7-hydroxy 
coumarin and screened them for anticancer activity which have potential activity 
against DMBA-induced skin cancer in mice
[60]
. 
O O
CH3
OH
 
 Xin-Hua liu et al., (2010), reported the synthesis of novel coumarin 
derivatives containing 4,5-dihydropyrazole moiety which exhibited potential 
antitumor activity
[61]
. 
 
 
N
N
O
CH3
O
R
R=4-OCH
3
,4-OH,2-Cl,H,2,4-Cl
 
 
7. Coumarins with Antioxidant activity 
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 Melagraki et al., (2009), evaluated a series of coumarin-3-carboxamides 
for their in-vitro antioxidant activity and in-vivo anti-inflammatory activity. These 
derivatives were found to posses these activities
[62]
. 
 
O O
R
OH
NH
X
NH2
O
 
 Singh et al., (2010), tested 3-alkanoyl/aroyl/heteroaroyl-2H-chromene-2-
thiones for their free radical scavenging capacity towards the stable free radical 
2,2-diphenyl-1-picrylhydrazyl (DPPH). These compounds exhibited profound 
antioxidant activity
[63]
. 
O
O
R1
R2
R3
O
 
 Roussaki et al., (2010), evaluated a series of coumarin analogues bearing 
a substituted phenyl ring on position 3 for their antioxidant activity by using two 
different antioxidant assays
[64]
. 
O O
R'
R
R3
R2
R1
 
 
 
8. Coumarins with Antihyperlipidemic activity 
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 Sashidhara et al., (2010), evaluated a series of coumarin bisindole 
heterocycles for antihyperlipidemic activity in hyperlipidemic hamster model.And 
showed a promising activity
[65]
. 
O O
N
S
NH
NH
N
R1
R2
O
 
9. Coumarins with Anticonvulsant activity 
 Bhat et al., (2006), were synthesized a novel thio ureido derivatives of 
sulfonamides and thiosemicarbazido derivatives of coumarin and reported them as 
potential anti-Convulsant agent
[66]
. 
 
O O
NH
NH NHR
O
S R=C6H5,p-Br,p-Cl-C6H4,p-CH3-C6H4
 
 Siddiqui et al., (2009), tested some heteroaryl semicarbazones for their 
anticonvulsant activity using pentylenetetrazole (PTZ) induced seizure, maximal 
electroshock seizure (MES) and Neurotoxicity tests.The compounds having 3,4-
Cl.C6H3, 2-OCH3.C6H4 and 4-Br.C6H4 exhibited significant anticonvulsant 
activity
[67]
. 
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O
O O
O
R
N
R1
R2
N
R1
R2
R-H,CH3
R1-CH3, OH
R2-H,CH3
 
 
10. Coumarins with Antiparkinsonian activity 
 Matos et al., (2009), Evaluated a series of 8-bromo-6-methyl-3-
phenylcoumarin derivatives as MAO-A and MAO-B inhibitors using R-(-)-
deprenyl (selegiline) and Iproniazide as reference inhibitors
[68]
. 
O O
CH3
Br
R
 
11. Coumarin with Anticoagulant activity 
 Abdelhafez et al., (2010), were synthesized 3-Pyridinyl, pyrimidinyl and 
pyrazolyl-4-hydroxycoumarin derivatives and a comparative in vivo (CT, PT 
determination) and in vitro (measurement of PIVKA-II levels) anticoagulant study 
with respect to warfarin showed that the synthesized compounds have different 
anticoagulant activities, the most prospective compounds were the 3-pyrazolyl-4-
hydroxycoumarin derivatives
[9]
. 
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12. Coumarin with Anti HIV activity 
 Releva et al., (2005), were synthesized 3,3’-arylidene-bis-4-hydroxy 
coumarins and were shown to exhibit prominent anti HIV activity
[69]
. 
 
O
O
OH
O
O
OH
R
R=4-Br,4-OCH
3
,2-OCH
3
,2,4-diOCH
3
,
2,3-diOCH
3
 
 Hwa et al., (2008), were synthesized some new benzimidazole coumarin 
conjugates which exhibited anti hepatitis C antiviral activity
[11]
.  
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N
N
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O
R
3
R
4
R
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CHEMISTRY OF PYRAZOLE 
1. Anti-Diabetic activity of pyrazoles 
 Raafat Soliman et al., (1982), Investgated for three series of 3,4,5-
trisubstituted pyrazolesulfonylurea derivatives were prepared and evaluated as 
hypoglycemic agents. Preliminary biological testing revealed that the new 
compounds possess moderate hypoglycemic activity
[70]
.  
 
N
N
SO2NHCONHR
CH3YOOC
N
N
SO2NHCXNHR
CH3HOOC
H5C6 N
N
CH3
X
CONHH5C6
SO2NHCONHR
 
 Hassan M. Faid-All et al., (1987), investigated a series of substituted  
p(3,5-diaryl-2-pyrazoline-l) benzenesulfonylurea and thiourea derivatives, along 
with their corresponding substituted p(3,5-diaryIpyrazole-l) benzenesulfonylurea 
and thiourea derivatives, were prepared for evaluation as hypoglycemic agents. 
Preliminary biological testing revealed that the new compounds possess potent 
hypoglycemic activity
[71]
. 
N N
Y'
Z
SO2NHCXNHR  
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 Honnalagere Ramesh Puneeth et al., (2015), Performed an Evaluation of 
in-vitro antidiabetic ability of curcumin pyrazole derivatives by the inhibition 
studies of the digestive enzymes, including alpha-amylase, rat intestinal alpha-
glucosidase, and sucrose and showed a prominent inhibition of the enzymes
[72]
 
N N
R
OH
OH
OH
OH
 
 R.Kenchappa et al., (2017), done a synthesis of series of 6-substituted -3-
(1-(4- substituted)-4- ((2)-95,6- dimethoxy-1-oxo-1H-inden-2(3H)-ylidene) 
methyl-1H-pyrazol-3-yl)- 2H-chromen-2-one derivatives and screened which 
posses potent anti oxidant and anti hyperglycemic agents, against chemically 
induced adult wistar rats
[73]
. 
 
O
O
R
N N
R
1
O
OH
OH
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13. Antimicrobial activity of Pyrazoles 
 Bhawsar et al., (1999), were synthesised some new coumarino pyrazoles 
evaluated them for antimicrobial activity
[74]
. 
N
N
Het-O
O
OH
R
R1
OO OH
CH3
OO CH3
CH3
CH3
,
Het=
R=Cl,CH
3
R
1
=CH
3
,OCH
3
,H
 
 Sah et al.,(2002),  reported the synthesis of substituted pyrazoles bearing 
2-aryl amino -5- mercepto-1,3,4- thiadiazole nuclei as possible antimicrobial 
agents
[75]
. 
NH N
S
N
S
O2N
N
O
N
CH3
CH3
R1
R
1
=H,Cl
 
 Faidallah et al., (2002), were synthesised 3,5-disubstituted pyrazoles from 
chalcones. Their antimicrobial activities have been examined successfully
[76]
.  
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R
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 Hiremath et al., (2002), were synthesised substituted pyrazoles, 
pyrazolones and 3,5-disubstituted pyrazolines which exhibited antimicrobial 
activity
[77]
. 
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N
N
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 Garg et al., (2002), were synthesised 1-thiocarbonyl 3-trifluoro methyl-5- 
phenyl-4(2-fluro phenyl azo) pyrazoles. These compounds showed significant 
antibacterial activity against S.aureus, S.typhi and E.coli
[78]
. 
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 Garkwad et al.,(2004), synthesised certain N-1-[2-hydroxy benzoyl]- 5 –
substituted phenyl-3- phenyl 4,5- dihydro pyrazoles and screened them for 
antimicrobial activity
[79]
. 
 
N
N
OH
O
C6H5
R
R=Cl,OCH
3
,NO
2
 
 
 Mistry et al., (2009), succeeded in the synthesis of a series of pyrazolo 
(5,4-d) – pyrimidine derivatives which exhibited antimicrobial activity[80]. 
R1
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N
N
N
CH3
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 Vijaykumar et al., (2010), synthesised novel 1,5 diaryl pyrazole 
derivatives which exhibited good antibacterial and antifungal activities
[81]
. 
N
N
N
O
O
Cl
F
 
14. Antioxidant activity of pyrazoles 
 Padmaja et al., (2009), were synthesised substituted pyrazoles which 
possessed good antioxidant activity
[82]
. 
 
N
N
NH2
NH2
RO
O
R
R=ClC
6
H
4
(p)
 
 
15. Antimalarial activity of pyrazoles 
 Vishnu et al., (1994), reported the synthesis of a few pyrazoles and these 
compounds were screened for anti malarial activity
[83]
. 
 
N
H
N
NH2
NH2
R
R=C
6
H
5
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3
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16. Antitumour activity of pyrazoles 
 Fathalla et al., (1998), were synthesised 3-cyano-(p-antipyryl amino)- 
pyrazolo pyrimidines and pyrazolo triazines. Several biological activities have 
been established for pyrazolo derivatives. Various related compounds of this class 
have been found to be anti tumour and anti lukemic agents
[84]
.  
 
N
N
CH3
CH3
O
NH
N N
N
NH2
X
CN
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2
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17. Anti inflammatory and Analgesic activity of pyrazoles 
 
 Rao et al., (1996), were synthesised 2-(3-aryl-4-formyl pyrazol-1-yl) 3-
phenyl-1,8- napthyridines. It was reported that these compounds exhibit anti-
inflammatory activities[
85]
. 
   
N N N
N
R
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C6H5
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6
H
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 Sharma et al., (2002), were synthesised indolyl-thiadiazolyl- pyrazolines 
and indolyl- oxadiazolyl pyrazolines which showed anti-inflammatory activity
[86]
. 
 
N
H
N N
S NH
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N
R COCH3
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H
N N
O NH
N
N
R COCH3
OH
OCH3
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 Amir et al., (2005), synthesised 3,5-dimethyl pyrazoles and evaluated 
their analgesic, ulcerogenic and anti inflammatory activities
[87]
. 
 
N
N
CH3
CH3
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18. Anticonvulsant activity of Pyrazole 
 Nagihan Beyhan et al., (2013), Investigated 5-Disubstituted-4,5-dihydro-
1H-pyrazole-1-carbothioamides and  N-3,5-trisubstituted-4,5-dihydro-1H-
pyrazole-1-carboxamides were synthesized. All compounds were tested for their 
anticonvulsant activity using pentylenetetrazole induced sei-zure (PTZ) and 
maximal electroshock seizure (MES) tests in mice which exhibited a potent 
activity in the tests
[88]
.  
N
N
Ar1
Ar2O
NH
Cl
N
N
Ar1
Ar2S
NH2
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CHEMISTRY OF ISOXAZOLE 
1. Antidiabetic activity of Isoxazole 
 G Mariappan et al., (2011), investigated  a series of  novel 4-arylidine 2-
[4-methoxy phenyl] oxazol-5-one derivatives were synthesized and assayed in 
vivo to investigate their antidiabetic activities by streptozotocin-induced model in 
rat and shows prominent activity
[89]
. 
 
N
O
O
O
CH3
N
O
O
O
CH3
O
 
 
 Lincy Joseph et al., (2016), investigated a series of novel Isoxazoles 
derivatives. The prepared isoxazole compounds were subjected to in vitro anti-
diabetic screening by yeast and enzymatic method. All compounds were screened 
for antibacterial action by disc diffusion method. 5-C and amine substituted 
phenyl ring at 3-C of isoxazole exhibited moderate anti-bacterial activity. In the 
anti-diabetic study halogenated or nitrated phenyl ring at 5-C and hydroxyl/amine 
substituted phenyl ring at 3-C of isoxazole exhibited anti-diabetic action
[90]
. 
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2. Antimicrobial and  anti-inflammatory activity of Isoxazole 
 S. S. Panda et al., (2009),  investigation of Indolyl-isoxazoles which has 
been synthesised and the compounds were tested for the acute antiinflammatory 
activity and antibacterial activity using carrageenan-induced rat paw edema 
method and cup-plate method and the results  exhibited good activity
[91]
. 
NH O
N
R
 
 M. T. Shreenivas et al., (2011), investigated a series of isoxazole 
derivatives have been synthesized, The newly synthesized title compounds were 
screened for their in vitro antimicrobial activity. The compounds N-(2-chloro-5-
nitrophenyl)-5-methylisoxazole-4-carboxamide and N-(4-cyano-3-(trifluoro-
methyl)-phenyl)-5-methylisoxazole-4-carbox-amide are shown good antibacterial 
and anti fungal activity
[92]
. 
N
O
NH
R2R1
O
O
 
 
 Sathish N.K et al., (2011), investigation of novel isoxazole derivatives 
were synthesized from various unstable Chalcones. The synthesized isoxazoles 
were evaluated for their anti-inflammatory activated and showed significant 
activity when compared to standard Diclofenac sodium
[93]
. 
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O NR3
R2
R1
R4
 
 Kamala Chand Gautam et al., (2013), investigated a series of new  
isoxazole derivatives of thiophene were synthesised and the compounds were 
screened for antimicrobial activity by disc diffusion method. The result suggested 
that the four compounds were moderately to highly active
[94]
. 
N OS
R
R-4C
8
H
7
O,3-NO
2
4-NO
2,
3-OCH
3
,3-Cl,3-CH
3
 
 Babasaheb V. Kendre et al., (2015), investigated a new series of 
pyrazole, isoxazole, benzoxazepine, benzothiazepine and benzodiazepine 
derivatives were prepared and all the synthesized compounds were evaluated and 
screened for their anti-bacterial, antifungal activities and anti-inflammatory 
activity. These derivatives showed good antibacterial activity and antifungal 
activity. Among the tested compounds for anti-inflammatory activity, the pyrazole 
derivatives have showed strong activity
[95]
. 
 
O
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O
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 Gollapalli Naga Raju et al., (2015), Synthesis of 3-substituted phenyl-5-
(2",2"-dimethyl, 7"-hydroxy chroman) isoxazoles. All the synthesized compounds 
were tested for their antibacterial and antifungal activity in vitro by broth dilution 
method with two Gram-positive bacteria, two Gram-negative bacteria and two 
fungal strains and these compounds showed promising results against those 
strains
[96]
. 
O
O N
OH
CH3
CH3
R
1
R
2
R
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3. Anticancer activity of Isoxazole 
 R. Kalirajan et al., (2012), synthesised  novel isoxazole-substituted 9-
anilinoacridine derivatives. The compounds were confirmed by physical and 
analytical data and screened for in vitro antioxidant activity by DPPH method, 
reducing power assay and total antioxidant capacity method and the cytotoxic 
activity of the compounds was also studied in HEp-2 cell line. All the isoxazole-
substituted compounds have significant activities
[97]
. 
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 Sherifa M. Abu Bakr et al., (2015), investigated a series of  5-substituted 
pyrazole derivative with isoxazole ring system were synthesised  and was  
evaluated against Panc-1 and Caco-2 cell lines. Most of the tested derivatives 
exhibited high cytotoxic potency against Panc-1 carcinoma cell lines, but 
moderate to weak activity was obtained against Caco-2 cell lines
[98]
.
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4. Antioxidant activity of isoxazole 
 KH. Kumar Naik et al., (2013), performed a synthesis of N/S/O 
functionalized Isoxazole ligands and their complexes ofMn(II), 
Fe(II),Ni(II),Co(II)and Cu(II) ions and evaluated for their antioxidant and 
antimicrobial activities which exhibited dominant antioxidant activity
[99]
. 
N O
R
R1
N O
R1
R
X-M-X
M=Mn(II),Fe(II),Ni(II),Co(II),Cu(II)
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5. Anti convulsant activity of Isoxazole 
 Udayan Banik et al., (2013),  tested on substituted 3-isoxazole esters, 3-
alkyl 5-aryl isoxazoles  were synthesised and evaluated for in vitro anticonvulsant,  
by using cell lines anticancer and antioxidant activities and showed prominent 
activities in isoxazole derivatives
[100]
. 
O N OC2H5
O
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CHEMISTRY 
 
CHEMISTRY OF COUMARIN 
 
INTRODUCTION 
 Coumarins, also known as benzopyrones, present in many plants, notably 
in high concentration in the tonka bean (Dipteryx odorata), vanilla grass 
(Anthoxanthum odoratum ) and sweet grass (Hierochloe odorata ). Their presence 
has been detected in a few microorganisms asnd also in few animal sources. 
 
Benzopyrones are of two types: 
• 2H-benzopyran-2-ones (or) coumarins 
• 4H-benzopyran-4-ones (or) chromones 
 
Derivatives 
 Coumarins is the lactone of 4-hydroxy cinnamic acid. Coumarins and all 
its derivatives are considered as phenyl propanoids which are roughly classified as 
follows. 
• Coumarins and simple derivatives: Hydroxy b) Methoxy c) Amino d) 
 Bromo and chloro e) Thio and f) Carboxylic acid derivatives of 
 coumasrins. 
• Furano coumarins 
• Pyrano coumarins 
 
 
Chemistry 
 
 
 
 
Department of Pharmaceutical Chemistry 54 
 Coumarin itself was first isolated in 1820 from tonka bean and it was first 
synthesized by perkin from salicylaldehyde and acetic anhydride. The 
biosynthesis of coumarin in plants is via hydroxylation, glycolysis and cyclisation 
of cinnamic acid. 
 
Physical data
[101]
 
Synonym  : 1,2- Benzopyrone, 2H-1-Benzopyran-2-one 
Chemical formula : C9H6O2 
Melting point  : 71° C 
Boiling point  : 301°
 
C  
Density  : 0.935 g/cm
3 
 
Dipole moment : 4.51D 
Solubility  :  Very soluble in boiling water 
 
 Coumarin in alkaline medium exhibits a green fluorescence in UV light. It 
has the characteristic odour that of vanilla beans and is used for the preparation of 
perfumes, soap and flavouring agents. 
 
METHODS FOR THE SYNTHESIS OF COUMARIN 
DERIVATIVES
[102,103]
 
 Among the few methods which have significant important results; there 
are several other methods whose applications are less general. All these methods 
center round the possibility of building up the pyrone ring on a suitable benzene 
derivative.  
1.  Knovenagel Reaction  
 Condensation of ortho-hydroxy aldehydes or ketones with active 
methylene compounds (diethyl malonate, malanonitrile) in the presence of a base 
(ammonia or amines) to form coumarins is known as Knovenagel reaction. 
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 When malonic acid and piperidine are used, the reaction is called Doebner 
modification. 
               
 
Mechanism 
Two mechanism have been proposed for the Knoevengal reaction 
 In one, the role of the amines is to form an imine or iminium salt which 
subsequently reacts with the enolate of the active methylene compound. 
Under normal circumstances, elimination of the amine would give the 
cinnamic acid derivative. However, when an O-hydroxy group is present 
in the aromatic aldehyde, intramolecular ring closure to the coumarin can 
occur. 
 
 In the second mechanism postulated, the carbanion derived from the active 
methylene compound by deprotonation by the amine is considered to 
attack the carbonyl group without further intervention by the base.                
                          
  
 
2.  The Pechmann synthesis 
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 It is the condensation of phenols with β-ketoesters in the presence of an 
acid catalyst (sulphuric acid). This is the most widely used method for the 
synthesis of coumarins. 
 When acetoacetic ester and its derivatives are used, the reaction is referred 
as Pechmann - Duisberg reaction. 
 
Mechanism 
 The Pechmann reaction is thought to proceed through the electrophilic 
aromatic substitution of resorcinol. The resulting β-hydroxy ester then undergoes 
dehydration and cyclisation to give coumarin. 
 
3.  Perkin reaction 
 W.H. Perkin prepared coumarin by heating salicylaldehyde with acetic 
anhydride and anhydrous sodium acetate. 2-hydroxy cinnamic acid (coumarinic 
acid) was first formed as the intermediate which gets lactonised to form coumarin. 
Along with coumarin O-acetyl coumarinic acid is also produced. 
  
OH
CHO
OH
COOH
O O
(CH3CO)2O
CH3COONa
-H2O
Mechanism 
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 Carbonyl carbon of aldehyde reacts with carbanion to give an intermediate, 
which on cyclization gives coumarin. Sodium acetate functions as basic catalyst. 
CH
3
COONa CH
3
COO- + Na+
CH
3
COOCOCH
3 CH3COO
-+ -CH2COOCH3+ CH3COOH
 
O
OH
+ -CH2COOCH3
OH
CH2COOCOCH3
O
-
H
H+
CH3COOH
OH
OH
H CH2COOCOCH3
-H2O
OH
CH=CHCOOCOCH3
O O
-CH3COOH
 
4.  Wittig reaction  
 In this method, carbonyl compounds and phosphonium ylides react to form 
an alkene whose lactonisation will give coumarin derivatives. 
CHO
OH
R + Ph3P=CHCOOC2H5
Et2NPh
reflux
COOC2H5
OH lactonisation O O
R R
 
5.  Claisen condensation 
 The base catalysed intermolecular condensation of 1,3-dicarbonyl 
compound can give rise to coumarins. For example, in the presence of sodium 
ethoxide, diethyl 3-oxopentanedionate (acetonedicarboxylate) affords 6- 
ethoxycarbonyl-4,5,7- trihydroxy coumarin through an initial claisen condensation 
followed by Dieckmann reaction. 
EtO2CH2C
OH
EtO2C
-OEt CO2Et
EtO2C
O
CH3
CO2Et
O O
O O
OHOH
OH
EtO2C
+
O O
OHOH
OH
CO2Et
6.  Kostanecki – Robinson Reaction  
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 In this reaction, coumarins (usually 3 and 4 substituted) are formed by 
acylation of o-hydroxy aryl ketones with aliphatic acid anhydrides followed by 
cyclisation. 
O
R1
OH
+
R2
O R2
O O
R2CH2COONa
CH3
O
O
R2
O
cyclisation
O O
R1
R2
-hydroxyaryl 
ketone
acid anhydride
3,4-disubstituted 
coumarin
Chemical Properties
[104]
 
Reactivity of Coumarins 
 Coumarin and its derivatives are highly reactive because of the aliphatic 
moiety present in the coumarin, it is likely to undergo ring opening at the acyl 
centre. Carbon-6 on the aromatic ring can undergo electrophilic attack such as 
Friedel-Crafts acylation, sulphonation leading to the formation of 6-substituted 
derivatives. A methyl substituent on the coumarin nucleus may react differently 
depending on the position of attachment. Phenol group present in the C-7 position, 
easily undergo acylation, benzoylation and Friedel-Crafts reactions. 
 
Reactions of coumarin nucleus 
A. With Nucleophiles 
 Several kinds of nucleophiles react with coumarins. Some of these  
reactions involve ring opening and occasionally, recyclisation into another ring. A 
nucleophile (Nu) which cleaves the ring, attacks and breaks one of the bonds  of 
the ring oxygen atom as shown below. 
OH O
Nu
a
O O
OH
O
Nu
b
b a
 
1. With C-Nucleophiles 
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a. Grignard Reagents 
 Coumarins react with Grignard reagents, like esters, and give mixture of 
products,resulting from the ring opening of the initial carbonyl adduct. 
 
 
O OH
O
CH3
OMgI
CH3OMgI
O
MeMgI
Et2O/ 0
0 C
O
CH3
CH3 OH OH
CH3
CH3
10% 40%
Diazomethane 
 On reaction with nucleophilic carbon of diazomethane, 3-cyano and 3-
nitrocoumarin are readily converted into their 4-methyl homologues but coumarin 
is transformed into the pyrazolone. 
O O
R
CH2N2, 20
0 C
O O
CH3
R
R=H; CH2N2
00 C
COOMe
OMe
N N
O
R=CN, 90%
R=NO
2, 
59%
 
 
b. Methylsulphinylmethide 
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 Carbanions generated in situ by strong bases cleave pyran-2-one rings but 
acidification may result in the formation of a new compound. 
   
O O
OMe
+ MeSOCH2- Na+
CH2SOCH3
OMe
ONa O
H+
O
OH
OH
H3COS
O
O
CH2SOCH3
Chromone
 
2. With N-Nucleophiles 
a.  Aliphatic Primary and Secondary Amines: 
 Coumarins do not react with ammonia and amines to produce α-
quinolones, even under forced conditions. The reaction is not favourable since it 
involves a non-aromatic intermediate. 
 
b. Aromatic Primary and Secondary amines: 
 Coumarins react with primary aromatic and secondary cyclic amines to 
yield substitution products such as 4-arylamino and 4-piperidino coumarin. 
O O
NHAr
ArNH3
O O
OH
Piperidine
O
N
O  
 
 
3. With O-Nucleophiles Reaction with alkali 
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 The reaction of coumarins with hydroxides involves initial addition to the 
carbonyl carbon, followed by opening of the lactone ring to give yellow solutions 
of the salts of the corresponding cis-cinnamic acids (coumarinic acids). 
 
O O
COO
-
Na
+
O
-
Na
+ COOH
OH
dil.NaOH
hot
acid
2-Hydroxy-cis-cinnamic acid
 
B. With Electrophiles 
a. Chloromethylation 
 Chloromethylation occurs at C-3 position of coumarins by the reaction 
with formaldehyde in the presence of HCl or acetic acid and ZnCl2. 
 
O O
CH2O / HCl
AcOH / ZnCl2
O O
CH2Cl
 
b. Bromination 
 Coumarin reacts with one molecule of bromine to form th3,4-dibromide 
which readily eliminates hydrogen bromide to form 3-bromocoumarin. Reaction 
with bromine, in the presence of excess of aluminium chloride, yields 6-
bromocoumarin. 
O O
Br2 / CHCl3
O O
Br
H
H Br
-HBr
O O
Br
O O
Br
Br2/ AlCl3
 
 
c. Sulphonation 
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 Sulphonation of coumarin with chlorosulphonic acid at 100°C yields the 6-
sulphonyl derivative, but at 130-140°C, a second substituent is introduced to give 
3,6-disulphonyl chloride. 
O O
O O
ClO3S
O O
SO3ClClSO3H
1000C
ClSO3H
1600 C
 
d. Nitration 
 Nitration occurs mainly at C-6 position and under vigorous conditions, 
substitution occurs at C-3 position also. 
 
O O
HNO3
1000 C
O O
O2N
HNO3
160 oC
O O
NO2O2N
 
e. Mannich reaction[105] 
 Mannich reaction of 4-hydroxy coumarin with primary amines and 
formaldehyde resulted in the formation of 3-aminomethyl-4-hydroxycoumarins. 
O O
OH
HCHO
O O
N
R
1
R
OH
R-NH-R1
 
 Similarly, Mannich reaction of 3-hydroxy coumarin with formaldehyde 
and primary or secondary amines resulted in 4-N,N-dialkylaminomethyl-3-
hydroxy coumarins. 
O O
OH
HCHO
R-NH-R1
O O
N
R
1
OH
R
 
 
C. Reduction 
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a. Reduction with Diborane and Hydrogen peroxide 
 Reduction with diborane followed by hydrogen peroxide has two effects 
on coumarins: the carbonyl group is reduced to methylene and the elements of 
water are added across the 3,4-double bond in an anti-Markonikow manner but the 
overall yield is very low. 
 
O O
i) B2H6
ii)H2O2
O
OH
3,4-dihydro-h-chromone-3-ol
 
 
b. Reduction with Lithium aluminium hydride 
 Hydride reagents can react either at carbonyl carbon or the conjugate 
position and therefore mixtures of two compounds are produced. 
 
O O
LiAlH4
Et2O
CH2OH
OH
+
CH2OH
OH  
 
D. Hydrolytic Reaction 
 Coumarins hardly undergo hydrolysis by alkali to form coumarinic acids 
which are cis in form and can be converted to trans form by prolonged treatment 
with alkali. 
O O
COONa
OH
H
H
OH
COONa
NaOH
HCl
  
 On the other hand, substituted coumarins give a mixture of a phenol and a 
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ketone as a result of hydrolysis with alkali. 
O O
OH
CH3
Ph
33-50%
KOH
OHOH
+ CH3COCH2Ph
 
E. Diels Alder Reaction 
 Coumarins serve as dienophiles in Diels Alder reaction, but only under 
relatively strong conditions. 
O O
+
CH2
CH3
CH3
CH2
Xylene/ 260 oC
O
O
H
H
CH3
CH3
 
F. Ring Contraction Reaction 
 The reaction is a type of Perkin rearrangement reaction. The reaction 
proceeds with the bromination of coumarins. The resultant dibromocoumarin on 
Alkaline degradation gives coumarilic acid which is decarboxylated to 
benzofuran. 
O O
Br2
O O
Br
Br
KOH
-H2O
O
-
COO
-
Br
-Br-
O
COOH
Distillation
-CO2O
 
 
G. Photochemical Reactions[101] 
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 The photo dimerisation of coumarin has been studied in several    solvents 
and the nature of solvent has an effect on this complex reaction. 
1. In a polar medium such as methanol, the only product formed is the 
 cis head to head isomer. 
2. In a non-polar medium such as benzene or dioxane, trans head to head 
dimer is the main product of the reaction; small amounts of head to tail 
dimers are also formed in non-polar solvents. 
 
O O
h MeOH
h C6H6
O O
O O
HH
HH
O O
O O
H H
H H
+
O O
O O
Cis head to head isomer
trans head to head isomer
head to tail isomer
 
H. Vilsmeier-Haack Reaction 
 The reaction of an N,N-disubstituted formamide, such as DMFor N-methyl 
formanilide, with acid chlorides, such as phosphoryl chloride or phosgene,leads to 
the formation of an 'adduct’. These adducts are usually referred to as the 
Vilsmeier reagent which is used in the formylation of electron rich aromatic 
compounds or olefins. 
 
  
Formation of adduct:  
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N
CH3
CH3
O
H
POCl3
N
+
CH3
CH3
OPOCl2
H
N
+
CH3
CH3
Cl
H
DMF Cl- -POCl
2
 
Vilsmeier-Haack Reaction in 4-hydroxy coumarin: 
O O
POCl5
DMF
O O
OH
N
+
CH3
CH3
H
H2O / OH
O O
OH
CHO
3-formyl-4-hydroxycoumarin
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CHEMISTRY OF PYRAZOLE
[106-109]
 
 Pyrazole was first described by Buchner  who discovered it during the 
decomposition of pyrazole 3,4,5- tricarboxylic acid. Pyrazole is a colourless solid 
with a melting point of 70°C and is soluble in water. It possesses a penetrating 
pleasant smell. Pyrazole has a high boiling point of about 187° C. 
 
Synthetic methods 
 The pyrazoles can be synthesised by the following general methods. 
1. From Dicarbonyl Compounds 
 The  most  straight  forward  method  of pyrazole  synthesis  involves  a  
reaction  between  a  1,3-[dicarbonyl  compound  and  hydrazine  or its 
derivatives. A simple pyrazole  is  obtained  with  a  1,3-dicarbonyl  compound  
such  as  acetylacetone  on  treatment  with  hydrazine  or  phenyl  hydrazine. 
CH3COCH2COCH3
NH2NH2
-H2O
N
N
H
CH3
CH3
CH3COCH2COCH3
N
N
CH3
CH3
H5C6
C6H5NHNH2
-H2O
 
 The reaction probably proceeds via the formation of monohydrazone 
which cyclizes  under the experimental conditions. The principal drawback of this 
method is that unsymmetrical dicarbonyl compounds or a substituted hydrazine 
generally gives an isomeric mixture of two products. 
 
 
 
Chemistry 
 
 
 
 
Department of Pharmaceutical Chemistry 68 
2. From α,β- Ethylene Carbonyl Compounds 
 This consists of a reaction between α,β- ethylene carbonyl derivative and 
hydrazine. The former must contain an easily replaceable group at the β-position. 
This is illustrated in the following equation. 
H5C6
Cl C6H5
O
C6H5NHNH2
N
N
H5C6
C6H5
H5C6  
3. From 1,3-Dipolar Addition  
 A diazo compound adds to an acetylenic derivative which has its triple 
bond activated by an electron-withdrawing substituent. The reaction is usually 
carried out in a suitable solvent at room temperature. Diazomethane or methyl or 
ethyl diazoacetate is commonly employed. Thus methyl diazoacetate and methyl 
phenyl propiolate yield the following isomeric pyrazoles in equal amounts. 
H5C6
COOCH3
N
N
H
H3COOC
COOCH3H5C6
N2CHCOOCH3
+
N
N
H
H3COOC
C6H5H3COOC
From Other Ring Systems 
 Various heterocyclic compounds transform to pyrazoles under appropriate 
conditions. Syndone, for instance, and acrylonitrile result in pyrazole formation. 
The cyanopyrazoline formed as intermediate is immediately converted to 
pyrazole. 
O
N
N
+
H5C6
O
-
+ CH2 CHCN
70 oC
N
N
H5C6
+ +CO2 HCN
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CHEMICAL REACTIONS 
 Pyrazole is very stable and inert. In acid medium it exists as cation. 
Pyrazole are known to form coordinate complexes with several metal ions. 
 
1. Alkylation 
 The alkylation of the free NH group of pyrazoles proceeds with alkylating 
agents such as alkyl halides, diazomethane or dimethylsulphate. Substituted 
pyrazoles undergo alkylation to give a mixture of two isomeric products. Excess 
of alkylating agent causes quarternization.  
N
N
H
H3COOC
CH3
N
N
COOCH3
CH3
CH3
N
+
N
COOCH3
CH3
CH3
CH3
N
N
H
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2. Electrophilic Substitution 
 Pyrazoles are subject to electrophilic substitution and the attack takes place 
at position 4. The electrophilic attack on pyrazole takes place readily in neutral or 
basis media. Chlorination (SO2Cl2  or free Cl2) of pyrazole yields 4- 
Chloropyrazoles. Bromination  (Br2/ dioxane) similarly occurs at position 4. 
Nitration (HNO3/ H2SO4) and sulfonation also occurs at position 4, but under 
more severe conditions the reactiontakes place on the pyrazolium cation. Nitration 
of 1-phenylpyrazole can be carried out in such a manner so as to obtain any one of 
the three successive nitration products. 
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3. Reaction with Oxidizing and Reducing Agents 
 The pyrazole ring is remarkably stable to the action of oxidizing agents but 
the side chain may be oxidized to the carboxylic function. The oxidation proceeds 
well in the presence of alkaline permanaganate. Pyrazole and its derivatives have 
been reduced under a variety of conditions. Thus with Na/C2H5OH, 2-pyrazoline 
is obtained. 
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 The catalytic reduction of 1- phenylpyrazole yields both phenylpyrazoline 
and 1-phenylpyrazolidine. 
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4. Reaction with Nucleophilies 
 Halogens attached to a pyrazole nucleus are exceptionally inert and thus 
will not undergo displacement under the usual reaction condition. In 1- 
phenylpyrazole, the halogen is most reactive in the 5-positions, less so in 4-
position and least in the 3-position. The presence of electron-withdrawing groups 
markedly assists nucleophilic displacement of halogens. Pyrazole quarternary salts 
are particularly reactive in nucleophilic reactions and in these compounds 3 and 5 
halogen substitutents can readily be replaced by a variety of nucleophiles. Direct 
amination of pyrazole with sodalime has not been observed, but it rather causes 
ring opening and metallation with n-butyllithium takes place at the 5-position. 
Pyrazoles exist partly as anions and thus react with electrophiles as phenols and 
undergo diazo coupling, nitrosation and Mannich reaction. 
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5. Photochemical Reactions 
 The most important photochemical reaction  of pyrazole is its conversion 
to imidazole. 
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CHEMISTRY OF ISOXAZOLE
[110]
 
 Isoxazole is a five membered π-excessive heterocycle with oxygen (furan-
type) and nitrogen (pyridine – type) at the positions-1and -2, but differs from 
oxazole by the presence of N-O bond. The partially reduced form of isoxazole 
(dihydroisoxazole or isoxazoline) exists in three isomeric forms, depending on the 
position of double bond. The position of double bond may be represented by 
prefix Δ (delta) with superscript. The completely reduced form of isoxazole is 
known as 2,3,4,5- tetrahydroisoxazole ( isoxazolidine). 
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Pyridine-type nitrogen
furan-type oxygen
 
 Isoxazole is a colourless liquid (b.p.= 95°C, D.M = 2.75 ± 0.01 D in 
benzene and 3.1 ± 0.03 D in dioxane) with strong pyridine like odour. The boiling 
point of isoxazole is although lower than of pyrazole and imidazole but higher 
than that of oxazole and furan. The higher boiling point of isoxazole is attributed 
to the greater intermolecular association in isoxazole molecules involving 
pyridine-type nitrogen and hydrogen at C-3. 
 
Synthesis 
1. Reaction of β-Diketones with Hydroxylamine 
 This is the most general and widely used method which involves 
condensation- cyclisation (3+2 cyclisation) of β-diketones with hydroxylamine in 
the presence of an acid. The reaction proceeds via the monoxime intermediate 
which subsequently on cyclizative-dehydration leads to the formation of 
isoxazoles. 
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Enolization in β-diketones 
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 This reaction has been extended to involve the reaction of hydroxylamine 
hydrochloride with C-C-C system of varying functional groups. 
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2. Reaction of Nitrile N-Oxides with Alkenes and Alkynes 
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 The reaction of nitrile oxides, generated in situ by treating chloroximes 
with a base (triethylamine), with alkenes and alkynes results in isoxazoles via 1,3-
dipolar cycloaddition. 
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REACTIONS OF ISOXAZOLE 
Reactivity 
 Isoxazole contains furan-type oxygen and pyridine-type nitrogen at the 
positions- and -2, it is therefore considered to exhibit characteristic reactions of 
furan and pyridine. But isoxazole undergoes electrophilic substitutions more 
readily than pyridine and less readily than furan because of combined effect of 
both the structural effects in isoxazole, (i) the electron-withdrawing effect of the 
pyridine-type nitrogen and (ii) the electron-releasing effect of the furan-type 
oxygen. As position-4 in isoxazole is with high electron density, electrophilic 
substitution, therefore, occurs at the position-4. The electron-releasing 
substitutents at the position-3 and/or C-5 exert activating effect, while the 
electron-withdrawing substitutents at C-3 and/or C-5 exert deactivating effect on 
the isoxazole nucleus at the position-4. The substitutent at the position-5 exerts 
activating or deactivating effect on the position-4 more strongly than the effect 
exerted by the substitutent if present at the position-3. 
1. Reaction with Electrophiles 
a) Electrophilic attack at Nitrogen 
N-Alkylation 
 Isoxazole, although least basic among the azoles, undergoes  
N-alkylation when treated with alkyl iodides or sulfates with the formation of 
quaternary azolium salts. However, the isoxazolium salts with bulky  
N-substitutents are obtained by treating isoxazoles with an alcohol in the presence 
of perchloric acid. 
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b) Electrophilic  Attack at Carbon 
 Both the heteroatoms influence the electrophilic substitutions in isoxazole 
ring. The electron-withdrawinng nature of pyridine-type nitrogen retards the 
attack of electrophile, but the electron-releasing effect of the furan-type oxygen 
atom facilitates electrophilic attack in isoxazole nucleus. 
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2. Nitration 
 Isoxazole is nitrated at the position-4 by the nitrating mixture of 
concentrated  nitric and sulphuric acids under controlled conditions (35
0 
C- 40
°
C). 
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3. Sulfonation 
 Isoxazole ring is resistant to sulfonation, however sulfonated with oleum 
under drastic conditions with the introduction of sulfonic acid group at the 
position-4. But 5-phenylisoxazole is sulfonated by chlorosulfonic acid with the 
sulfonation of only phenyl ring at the meta- and para- positions. 
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4. Halogenation 
 Isoxazoles undergo halogenation with chlorine or bromine at the position-
4  with the formation of the corresponding 4-chloro- or 4-bromo- isoxazoles. 
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5. Oxidation 
 Isoxazoles are stable oxidizing agents, but unsaturated side chain and the 
oxygenated functional groups are oxidised to their corresponding acids. 
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6. Reaction with Nucleophiles 
a) Nucleophilic Displacement 
 Isoxazole with highest electron density at the position-4, it is therefore the 
preferred site for the electrophilic attack. The isoxazoles substituted with halogen 
atom at the position-4 will be less susceptible to nucleophilic substitution (SN
2
) 
reactions. However, the halogen atom at the position-5 can be replaced if position-
4 is substituted with the suitable activating substitutent. 
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 The halogen atoms at the 3- and 5- positons can be replaced by 
nucleophiles if activated by ring quaternization 
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b) Condensation Reactions 
 The methyl group at the position-5 will be more reactive than the methyl 
group at the position-3, if position-4 is substituted with an electron-withdrawing 
group. Thus, 5-methyl group with enhanced reactivity is easily condensed with 
aromatic aldehydes in the presence of diethylamine, but 3-methyl group remains 
intact. 
O
N
CH3O2N
CH3
+ ArCHO
O
N
CH3O2N
CH
CH
Ar
-
(C2H5)2NH
 
Chemistry 
 
 
 
 
Department of Pharmaceutical Chemistry 79 
c) Rearrangement 
 Isoxazoles (also other heterocycles with N-O bond), substituted with 
suitable side chains of three atoms (hydrazone, oximine and imidine) at carbon α- 
to the pyridine-type nitrogen, undergoe special type of thermal and base catalysed 
rearrangement, known as Boulton-Katrizky rearrangement, by following 
generalised mechanism 
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d) Photochemical and Thermal Reactions 
 Isoxazoles are photochemically or thermally transformed into oxazoles via 
2H-azirine intermediate. 
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PURPOSE AND PLAN OF WORK 
 
PURPOSE OF THE STUDY 
 Diabetes mellitus is a major endocrine disorder affecting nearly 10% of 
the population all over the World. It is characterised by hyperglycemia and 
disturbances of carbohydrate, protein and fat metabolisms, secondary to an 
abosolute or relative lack of the hormone insulin. The number of people in the 
world with diabetes has increased dramatically over recent years. It is also 
predicted that by 2030, India, China, and the United States will have the largest 
number of people with diabetes. Currently treatment of diabetes, in addition to 
insulin supplement includes many oral hypoglycemic agents along with 
appropriate diet and exercise. The treatment goal of diabetic patients is to 
maintain near normal levels of glycemic control, in both fasting and post-prandial 
conditions. 
 
  Postprandial hyperglycemia has been proposed as an independent risk 
factor for diabetes mellitus. Therefore, control of postprandial hyperglycemia is 
suggested to be important in the treatment of diabetes. One of the effective 
method to control diabetes is to inhibit the activity of α-amylase enzyme which is 
responsible for the breakdown of starch to more simple sugars( dextrin, 
maltotriose, maltose, and glucose). This is contributed by α-amylase inhibitors,  
which delays the glucose absorption rate thereby maintaining the serum  blood 
glucose in hyperglycemic individuals. This study is focussed to investigate the 
inhibitory potentials of the synthesised coumarin derivatives on α-amylase, the 
key enzyme responsible for carbohydrate hydrolysis. 
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PLAN OF WORK 
The steps involved in the present study are: 
Identification of the target site 
 
Virtual screening of certain compounds using iGEMDOCK software 
 
Lead molecule optimization by calculating drug likeness score 
 
Performing Molecular docking of the lead molecules 
 
 
Synthesis of analogs of lead molecules 
 
 
Spectral studies of synthesized compounds 
 
 
Evaluation of in vitro α-amylase inhibitory activity 
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EXPERIMENTAL SECTION 
DRUG DESIGN APPROACH 
IN SILICO STUDIES 
Softwares and Databases used  
 Accerlys discovery studio viewer  
 Molinspiration server  
 Accelrys accord for excel  
 RCSB protein data bank  
 Online SMILES translator  
 Autodock 4.2 which combines  
 Autodock tools 
  Python molecule viewer 1.5.6  
 Vision 1.5.6  
 Cygwin 64  
TARGET SELECTION  
 The present study was focused on Alpha amylase inhibitory assay. From 
the literature review and the current research on alpha amylase enzyme inhibitors, 
we have selected alpha amylase enzyme for the alpha amylase enzyme as the 
target for the present study. The pdb structure of Alpha amylase enzyme (1UA7) 
was downloaded from the RCSB protein data bank.  
LEAD SELECTION   
 The lead Pyrazole derivatives and Isoxazole derivatives of coumarin were 
selected based on several literature reviews.  
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DOCKING STUDIES FOR THE LEAD  
Aim      : To predict the bioactivity score of the ligands.  
Database   : RCSB protein data bank  
Protein selected  : Alpha amylase enzyme ( 1UA7) 
 Target proteins were downloaded from RCSB protein data bank and 
docking studies were performed.  
Steps involved in docking studies 
[41,111,112]
  
 Docking process is done with AutoDock 4.2  
 Conversion of refined enzyme into pdb format  
 Conversion of pdb format of ligand into pdbqt format  
 Preparation of grid box by setting grid parameters  
 Docking process by setting docking parameters  
 Saving the docked result as dlg file  
 Viewing the docked conformation   
 Taking snapshots of the interactions  
STEP I:  
Protein structure refinement   
  Alpha amylase enzyme was downloaded from RCSB Protein Data Bank 
(PDB) and the enzyme was refined before docking. The steps involved are:  
 Open Accelrys discovery studio viewer.  
 File  Open Select the enzyme file downloaded from  RCSB PDB.  
 Click View option and then click Hierarchy.  
 Click water molecules.  
 Click water molecule   select all water molecules   cut. 
 Select ligand, which is unnecessary and cut.  
 Save the molecule in a desired location  
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 STEP II  
Ligand file format conversion  
 The ligands which are desired are drawn in ChemSketch software.  
 ToolsClick Generate  Click SMILES notation (Simplified 
 Molecular  Input Line Entry System, which is a file format).  
 Save the SMILES in a word document.  
 Open the online smiles translator cactus. nci.nih.gov/services/ 
 translate 
 Upload the SMILES.  
 By choosing the required file format and save the file in a pdb format  
 (e.g.:ligand.pdb).  
 Online smiles translator allows the user to convert SMILES format into 
PDB, MOL, SDF and smile text file format. Thus the selected ligand molecule of 
canonical smile format was converted to pdb format.  
 The protein and ligand files which are prepared by above said procedures 
are taken for docking.  
STEP III  
 Docking with autodock 4.2  
 Docking calculation in AutoDock was performed using the refined  protein 
 and the desired ligand in pdb format.  
Preparation and running a docking programme 
Preparing the protein  
 Open autodock 4.2  
 Open file    Click read molecule    Choose the  particular   refined 
 enzyme  file.  
 The elimination of the water is carried by the following steps.   
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  Press Select option  
 Click Select   click select from string option  
 Then write “*HOH*” in the Residue line &“*” in the atom line.  
 Click Add   No new selection and then dismiss.          
 Addition of  hydrogens is done by,  
 Press Edit  option 
 Click the Hydrogen 
  Then click Add  
 Choose all Hydrogen, No Bond Order, and „yes‟ to renumbering          
 click  Ok.  
 Next click    Edit option    click add the Kollmann Charges.  
 Then save the enzyme molecule as 1ea1refined.pdb  
 Select Edit  Delete     Delete all molecule  
Preparing the ligand  
 Confirm that all the hydrogens are added in the ligand.  
 Toggle the Auto Dock Tools button.  
 Open the Ligand   Click Input and choose the suitable ligand file and  
 finally open.  
 The torsions are designed by following steps 
 In the Ligand option select Torsion Tree 
 Select  Detect Root option  
 Click Torsion Tree  
 Then select the Choose Torsions option  
 Amide bonds should NOT be active.  
 After that click the Torsion Tree and select Set Number of Torsions  
 Number of rotatable bonds is chosen.  
 
 Finally Save the Ligand files by selecting the Output option (pdbqt 
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 file).  
 Select Edit   Delete    Delete all molecule.  
 Conversion of pdb files of protein into pdbqt file   
 Select the Grid option and open the Macromolecule pdb file.  
 Auto Dock adds the Charges and itself merges the Hydrogens.  
 Save the object as pdbqt in desired area.  
 AutoGrid Calculation and creating “gpf” file  
 Open the grid and click Macromolecule option and choose the rigid 
 protein then yes to preserve the existing charges.   
 The Preparation of grid parameter file is carried out by,  
 Open Grid  
 Select the Set Map Types  
 Choose Ligand  
 Accept it.  
Setting of  grid properties,  
 Open Grid 
 Select the Grid box  
 Set the proper Grid Dimensions(60.60.60)  
 Adjust the Spacing  
 Select the File and click Close Saving Current.  
 Save the grid settings as gpf file in the input option (ligand.gpf).  
 After running the grid file, the output automatically save as „glg‟ file  
Auto Dock calculation and creating ‘dpf’ file:  
 The rigid molecule specification is carried out by,  
 Select the Docking option  
 Click the Macromolecule   
 Set Rigid File Name.  
 The ligand specification is carried out by,  
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 Click the Docking option  
 Select the ligand   
 And then Accept it. 
  In the next step, click Docking option and select Search Parameters 
 in that  click Genetic Algorithm and finally accept it.  
 ClickDocking options   Select Docking Parameters  Choose the  
 Defaults.  
 Click Docking optionSelect Output and adds Lamarckian 
 Genetic  algorithm (LGA).  
 Save the docked settings as „dpf‟ file in the input option (ligand.dpf)  
 After running the docked file, the output automatically saves as „dlg‟ 
 file.  
Programming of ‘Auto Grid’ and ‘Auto Dock’execution:  
1.  Open Cygwin and typed as follows 
 cd c:  
 cd cygwin  
 cd usr  
 cd local  
 cd bin 
 Program should list out the pdb, pdbqt, gpf and dpf files of an enzyme and 
ligand molecule.  
2.  Then type as: ./autogrid4.exe <space> -p <space>ligand.gpf –l 
 <space>ligand.glg  
 If a ligand gets into the spacing of the grid, then the execution of this 
command will be;   
 ‘Successful completion’.  
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3.  Then type as: ./autodock4.exe<space> -p<space>ligand.dpf –
 l<space>ligang.dlg  
 If the ligand binds to the amino acids through 10 different conformations, 
then the execution of this command will be;  
 ‘Successful completion’. 
STEP IV   
Viewing docking results   
Reading the docking log file .dlg  
 Toggle the AutoDock Tools button  
 Click Analyze and Open Dockings.  
 In the next step, click Analyze option and Conformations then Load.  
 Double click on the conformation for to view it.  
Visualizing docked conformations  
 Click Analyze and Dockings then play.  
 Load dlg file   
 Choose the suitable conformations  
 In the next step, click Analyze and Docking then Show Interactions.  
Obtaining snap shots of docked pose   
 Open the File and Read the Molecule   
 Open Analyze    Click Dockings and Open dlg file   
 Open Analyze    Click Macromolecule and Choose pdbqt file. 
 Open Analyze     Click Conformations and Load   
 Double click the desired conformation  
 Click Analyze and Docking then Show Interactions.  
 Proteins and ligand interaction will be displayed. Zoom it and increase the  
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contrast by holding right key and ctrl.  
 Open File    Save image    cygwin/usr/local/bin as .png  
 The above mentioned steps involved in docking are done for all the 
 50  ligands. 
RESULTS AND DISCUSSION  
 The docking results of α-amylase (1UA7.pdb) with the 50 similar 
structural ligands are reported in the Table 1 and Table 2. The best docked 
structures should have lower binding energies. The binding sites and the active 
sites are shown in the snapshots. 
 
Fig 1: snapshots of 50 ligands 
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Table 1: Binding energies of 1-25 
Sl. No Compound code Binding energy k/cal 
1 Zinc_18249417 -90.53 
2 Zinc_20031600 -83.49 
3 Zinc_9365179 -75.59 
4 Zinc_19166762 -84.51 
5 Zinc_1700294 -94.06 
6 Zinc_841803 -71.13 
7 Zinc_3901268 -71.31 
8 Zinc_19799526 -82.5 
9 Zinc_982962 -102.76 
10 Zinc_19989886 -82.58 
11 Zinc_2258599 -96.1 
12 Zinc_19990070 -79.21 
13 Zinc_5556455 -95.45 
14 Zinc_19990034 -95.57 
15 Zinc_1240782 -94.08 
16 Zinc_19794473 -76.95 
17 Zinc_5286115 -95.45 
18 Zinc_984053 -95.57 
19 Zinc_5519407 -94.08 
20 Zinc_2758246 -76.95 
21 Zinc_8575396 -104.43 
22 Zinc_12378847 -108.44 
23 Zinc_6182368 -90.93 
24 Zinc_6219168 -94.9 
25 Zinc_19318821 -93.13 
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Table 1: Binding energies of 25-50 
Sl. No Compound code Binding energy k/cal 
26 Zinc_2063189 -66.85 
27 Zinc_18141403 -79.99 
28 Zinc_634140 -68.29 
29 Zinc_8442294 -67.43 
30 Zinc_8442293 -59.04 
31 Zinc_8442288 -55.47 
32 Zinc_651582 -62.16 
33 Zinc_8442281 -55.46 
34 Zinc_730699 -83.88 
35 Zinc_ 8442279 -69.79 
36 Zinc_8442278 -77.97 
37 Zinc_8442277 -71.89 
38 Zinc_8442276 -62.55 
39 Zinc_8442275 -78.22 
40 Zinc_8442273 -60.38 
41 Zinc_8442272 -86.63 
42 Zinc_8442271 -73.91 
43 Zinc_8442270 -88.19 
44 Zinc_8442268 -60.29 
45 Zinc_8442295 -93.49 
46 Zinc_634138 -83.9 
47 Zinc_1019824 -78.77 
48 Zinc_8442266 -88.9 
49 Zinc_8442267 -81.93 
50 Zinc_8442265 -76.15 
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 The binding energy of all the 50 compounds selected and the lowest 
binding energies were found to be Table 1 -104.43, -108.44 and Table 2 -93.49, -
88.9 which possess coumarin moiety. So that, in this project, we are only 
concerned coumarins as lead molecule. In the series of 50 ligands, the binding 
energy of 22(table 1) (-108.44) and 20 (table) (-93.49)  is the lowest binding 
energy. Hence, total of Ten compounds with similar structure as that of 
Zinc_12378847 and Zinc_8442266 is selected, to which Isoxazole and pyrazole 
moieties were attached and forms a new series of coumarins derivatives and 
carried to further studies. Therefore, this series include Isoxazole compounds I1-5 
and Pyrazole compounds T1-5 with coumarin ring system. 
Binding of Acarbose with α-amylase enzyme 
 Acarbose interacts with α-amylase enzyme at  ASP212A, YS179A, 
ASN273A, TYR59A, GLn63A, Gln126A, Leu142A, HIS180A, and 
GLu208A.Binding energy was found to be  -16.67  kcal/mol. 
 
Figure 2.Snapshot of I1binding with 1UA7 
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Binding of Isoxazole compounds with α-amylase enzyme 
I1  
 I1 interact with α-amylase enzyme at ASP212A, LYS179A, ASN273A, 
TYR59A, GLn63A, Gln126A, Leu142A, HIS180A, and GLu208A. Binding 
energy was found to be -11.2kcal/mol. 
 
Figure 3.Snapshot of I1 binding with 1UA7 
I2 
 I2 interact with α-amylase enzyme at ASP212A, LYS179A, ASN273A, 
TYR59A, GLn63A, Gln126A, Leu142A, HIS180A, and GLu208A. Binding 
energy was found to be -5.89 kcal/mol. 
 
Figure 4.Snapshot of I2 binding with 1UA7 
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I3 
 I3 interact with α-amylase enzyme at ASP212A, LYS179A, ASN273A, 
TYR59A, GLn63A, Gln126A, Leu142A, HIS180A, and GLu208A. Binding 
energy was found to be -7.32kcal/mol. 
 
Figure 5. Snapshot of I3 binding with 1UA7 
I4 
 I4 interact with α-amylase enzyme at ASP212A, LYS179A, ASN273A, 
TYR59A, GLn63A, Gln126A, Leu142A, HIS180A, and GLu208A. Binding 
energy was found to be -12.15 kcal/mol. 
 
Figure 6.Snapshot of I4 binding with 1UA7 
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I5 
 I5 interact with α-amylase enzyme at ASP212A, LYS179A, ASN273A, 
TYR59A, GLn63A, Gln126A, Leu142A, HIS180A, and GLu208A. Binding 
energy was found to be -8.83 kcal/mol. 
 
Figure 7.Snapshot of I5 binding with 1UA7 
Binding of Pyrazole compounds with α-amylase enzyme 
T1 
 T1 interact with α-amylase enzyme at ASP212A, LYS179A, ASN273A, 
TYR59A, GLn63A, Gln126A, Leu142A, HIS180A, and GLu208A. Binding 
energy was found to be -14.08 kcal/mol. 
 
Figure 8.Snapshot of T1 binding with 1UA7 
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T2 
 T2 interact with α-amylase enzyme at ASP212A, LYS179A, ASN273A, 
TYR59A, GLn63A, Gln126A, Leu142A, HIS180A, and GLu208A. Binding 
energy was found to be -9.14 kcal/mol 
 
Figure 9.Snapshot of T2 binding with 1UA7 
T3 
 T3 interact with α-amylase enzyme at ASP212A, LYS179A, ASN273A, 
TYR59A, GLn63A, Gln126A, Leu142A, HIS180A, and GLu208A. Binding 
energy was found to be -12.15 kcal/mol 
 
Figure 10. Snapshot of T3 binding with 1UA7 
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T4 
 T4 interact with α-amylase enzyme at ASP212A, LYS179A, ASN273A, 
TYR59A, GLn63A, Gln126A, Leu142A, HIS180A, and GLu208A. Binding 
energy was found to be -6.00 kcal/mol. 
 
Figure 11. Snapshot of T4 binding with 1UA7 
T5 
 T5 interact with α-amylase enzyme at ASP212A, LYS179A, ASN273A, 
TYR59A, GLn63A, Gln126A, Leu142A, HIS180A, and GLu208A. Binding 
energy was found to be -5.87 kcal/mol. 
 
Figure 12 . Snapshot of T5 binding with 1UA7 
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TOXICITY STUDIES  
 Pharmacokinetic properties of the selected lead compounds were checked 
to ensure the safety and efficacy.  
Toxicity studies are performed by two methods: 
 Evaluation of drug likeness property  
 Evaluation of ADME data  
Evaluation of drug likeness properties
[113]
  
 For the better oral absorption of the ligands, the drug likeness scores are 
constructed by getting information about the solubility, diffusion, Log P, 
molecular weight etc. One of the ideal method for this is using Lipinski‟s rule of 
five with the Molinspiration server.  
Calculation of Lipinski’s rule of five 
1.  Open the Molinspiration home page.  
2.  Click calculation of molecular properties and prediction of  bioactivity.  
3.  Draw the structure of I1 in JME window or paste the smile notation 
 of the compound.  
4.  Then click calculate properties.  
5.  Save the properties.  
6.  JAVA program is required in the computer for the calculation of the 
 properties.  
 Calculation of properties of the rest of the compounds is done in the same 
manner. 
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RESULTS AND DISCUSSION 
S.NO 
Compound 
code 
M Log p 
Molecular 
weight 
No. of H 
acceptors 
No. of 
H donors 
No. of 
violation 
1 I1 3.35 291.31 4 1 0 
2 I2 3.98 329.27 4 1 0 
3 I3 3.43 336.30 7 0 0 
4 I4 2.99 351.36 6 1 0 
5 I5 3.36 335.31 6 1 0 
6 T1 3.21 341.42 5 3 0 
7 T2 3.84 383.86 5 3 0 
8 T3 3.29 394.41 8 2 0 
9 T4 2.86 409.47 7 3 0 
10 T5 2.55 395.44 7 4 0 
 
 In addition to ligand-protein complex modeling, in vivo absorption 
capabilities of the designed molecules were tentatively assessed by means of 
Lipinski‟s rule of five that predicts that a compound administered orally will more 
likely have a good absorption or permeation. All the compounds satisfy the rule 
which indicates that all the ligands I1-5 and T1-5   have good oral absorption. 
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SYNTHESIS 
 
MATERIALS AND METHODS 
Chemical and Reagents used 
 Salicylaldehyde, ethylacetoacetate, piperdine, aromatic aldehyde 
[benzaldehyde, chloro benzaldehyde, nitro benzaldehyde, veratraldehyde, 
vanillin], rectified spirit (ethanol), sodium hydroxide, hydroxylamine HCl, sodium 
acetate. 
Apparatus used 
 Beakers, conical flask, round bottom flask, test tubes, pipettes, glass rods, 
funnels, watch glass, magnetic stirrer and TLC plates. 
Analytical work 
 Melting points were determined by using melting point apparatus MR-
VIS, Visual Melting Range Apparatus LABINDIA and were uncorrected 
in the department of pharmaceutical chemistry, college of pharmacy 
SRIMPS, Coimbatore. 
 Reactions were monitored by thin layer chromatography (TLC) on a 
precoated silica gel G plates using Iodine vapour as visualising agent. 
 The compounds purity are recorded on JASCO V-530 UV\V is 
spectrophotometer in the department of pharmaceutical analysis college of 
pharmacy SRIPMS, Coimbatore. 
 IR spectra is recorded on JASCO FT\IR-140 spectrometer in the 
department of pharmaceutical analysis college of pharmacy SRIPMS, 
Coimbatore. 
 PMR spectra were recorded on BRUKER ULTRA SHIELDED NMR-400 
MHz at VIT UNIVERSITY, Chennai. 
 MASS spectra were recorded on GCMS at VIT UNIVERSITY, 
 Chennai. 
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SCHEME I 
 
O
OH
Salicylaldehyde
+
OEt
O
OEt
O
Ethylacetoacetate
Piperidine
RT, 5mins
O O
CH3
O
3-Acetyl coumarin
+
O
R
Aromatic 
aldehyde
NaOH4-5 hours, stirring
O O
O
R
Chalcone
+
NH2 NH
NH2
S
Thiosemicarbazide
8 hours reflux
O O
N N
NH2
S
R R
1
T1-T5
 
 
Compound code R R
1 
T1 H H 
T2 Cl H 
T3 NO2 H 
T4 OCH3 OCH3 
T5 OH OCH3 
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SCHEME II 
O
OH
Salicylaldehyde
+
OEt
O
OEt
O
Ethylacetoacetate
Piperidine
RT, 5mins
O O
CH3
O
3-Acetyl coumarin
+
O
R
Aromatic 
aldehyde
NaOH4-5 hours, stirring
O O
O
R
Chalcone
+3 hours reflux
O O
O N
R R1
NH
2
OH.HCL
Hydroxylamine 
hydrochloride
I1-I5
 
 
Compound R R1 
I1 H H 
I2 Cl H 
I3 NO2 H 
I4 OCH3 OCH3 
I5 OH OCH3 
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Procedure 
Step 1: Synthesis of 3-acetyl coumarin
[114]
 
 A mixture of salicylaldehyde (0.204 mole) and ethylacetoacetate (0.255 
mole) was cooled and maintained at 0°-5°C, piperidine was added dropwise to the 
mixture while stirring (Doebner modification). The reaction mixture was left 
overnight, resulting the formation of a yellow coloured solid, the solid thus 
obtained was filtered and recrystallized with ethanol to give 3-acetyl coumarin as 
fine yellow needles. 
Step 2: Synthesis of chalcone
[115]
 
 Equimolar quantities of substituted various aromatic aldehydes and 3-
acetyl coumarin was taken in 250ml beaker, which was dissolved in 10ml of 
rectified spirit (ethanol). This mixture was stirred using mechanical stirrer at 20°-
25°C. While stirring NaOH (30%) was added dropwise to this mixture for 30mins, 
the solution becomes turbid, and continued stirring for 4-5 hours by maintaining 
the temperature. After stirring has completed the reaction mixture was neutralised 
by using 0.2 N HCl, where by the precipitate occurs. It was filtered and the crude 
chalcone was dried in air and recrystallised with ethanol. 
Step 3: 
 Synthesis of  Pyrazoles
[116]
 
 A mixture of chalcones (3 mmole), and thiosemicarbazide (14mmole) was 
refluxed in ethanol (50ml)  containing 0.5ml of concentrated hydrochloric acid for 
8 hours and poured on 100gm of crushed ice. The residue thus obtained was 
filtered and recrystallised with methanol. 
 
Synthesis of Isoxazoles
[116]
 
 A mixture of chalcones (0.015 mole), hydroxylamine hydrochloride (0.015 
mole) and sodium acetate (0.015mole) in 25ml of ethanol was refluxed for 6 
hours, the mixture was concentrated and poured on 100gm of crushed ice. The 
residue thus obtained was filtered and recrystallised with methanol. 
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PHYSICAL CHARACTERISATION DATA 
1) Substituted Isoxazoles 
O O
O N
R R1
 
Table 3: Physical characterization of substituted Isoxazoles 
Compound 
code 
R R1 Molecular formula 
Molecular weight 
(g/mol) 
% yield Melting point Rf value 
I1 H H C18H13NO3 291.300 58.25% 174-175
0 
C 0.57 
I2 Cl H C18H12ClNO3 329.27 88% 115-117
0 
C 0.60 
I3 NO2 H C18H12N2O5 336.298 70% 167-179
0 
C 0.39 
I4 OCH3 OCH3 C20H17NO5 351.352 55% 121-123
0 
C 0.51 
I5 OH OCH3 C19H15NO5 337.326 57.9% 167-179
0 
C 0.32 
Recrystallisation :Methanol 
Solvent system :10% Ethylacetate in hexane  
Visualizing agent  :Iodine vapour  
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2)  Substituted Pyrazoles 
O O
N N
NH2
S
R R1
 
Table 4: Physical characterization of substituted Pyrazoles 
 
Recrystallisation :Methanol 
Solvent system :10% Ethylacetate in hexane  
Visualizing agent  :Iodine vapour  
Compound 
code 
R R1 Molecular formula 
Molecular weight 
(g/mol) 
% yield Melting point Rf value 
T1 H H C19H15N3O2S 341.406 67% 177
0 
C 0.56 
T2 Cl H C19H14ClN3O2S 383.851 76% 172
0 
C 0.42 
T3 NO2 H C19H14N4O4S 394.403 87% 188
0 
C 0.66 
T4 OCH3 OCH3 C21H19N3O4S 409.458 46% 166
0 
C 0.43 
T5 OH OCH3 C20H17N3O4S 35.431 57% 169
0 
C 0.77 
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SPECTRA ANALYSIS 
SPECTRAL ANALYSIS OF COMPOUNDS
[117-119]
 
 The structures of synthesized compounds were established on the basis of 
chemical datas IR, UV, NMR and MASS spectra. The purity of all the compounds 
was established by single spot on TLC plates. 
Compound code: I1 
O O
NH
O
 
 
 
Chemical name 
3-(3-phenyl-2,3-dihydro-1,2-oxazol-5-yl)-2H-
chromen-2-one 
UV Spectrum Solvent used: Methanolλmax : 276 
IR (KBr, vmax in cm
-1
) 
3433(N-H),1635.34(coumarinylC=O), 
1384.04(C=C), 1099.23(C-O), 1041.37 (N-O), 
697.14 (Aromatic C-H) 
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Figure 13:UV Spectrum of I1 
 
Figure 14: IR Spectrum of I1 
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Compound Code: I2 
O O
O N
H Cl
 
Chemical name 
3-[3-(2-chlorophenyl)-2,3-dihydro-1,2-oxazol-5-yl]-
2H-chromen-2-one 
UV Spectrum 
Solvent used: Methanol 
λmax : 275 
IR (KBr, vmax in cm
-1
) 
3339.89(N-H),2357.55(Aromatic C-H),1635.38 
(coumarinyl C=O), 1488.78 (Aromatic 
C=C),1384.64 (C-O),754.995 (C-Cl),  
1
H
 
NMR spectral data 
δ 1.22 (s, 2H isoxazole ring),  δ 6.96 (s, 1H NH), δ 
7.470- 8.04 (m, 8H ArH), δ 8.57 (s, 1H coumarin 
(CH) ),  
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Mass Spectral Data 
Molecular weight of the compound: 329 
S/No Fragments m/z values 
1 O
O O N
H Cl
+
 
329.27 
2 
O O
CH3
+
 
167 
3 
O O
+
 
149 
4 
O
N
+
 
71.09 
 
 
 
 
Figure 15: UV Spectrum of I2 
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Figure 16: IR Spectrum of I2 
 
Figure 17: Mass Spectrum of I2 
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Figure 18: NMR Spectrum of I2 
 
Compound Code: I3 
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O O
O N
H
O2N
 
Chemical name 
3-[3-(2-nitrophenyl)-4,5-dihydro-1,2-oxazol-5-yl]-
2H-chromen-2-one 
UV Spectrum 
Solvent used: Methanol 
λmax : 264 
IR (KBr, vmax in cm
-1
) 
3443.28(NH), 1634.38 (coumarinyl C=O), 
1529.27(C-O),1457.92(C=C), 
1384.29(CNO2),687.498 (Aromatic C-H) 
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Figure 19: UV Spectrum of I3 
 
Figure 20: IR Spectrum of I3 
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Compound Code: I4 
O
O
O
CH3
O
CH3
O
N
 
 
Chemical name 
3-[3-(3,4-dimethoxyphenyl)-2,5-dihydro-1,2-
oxazol-5-yl]-2H-chromen-2-one 
 
UV Spectrum 
Solvent used: Methanol 
λmax : 276 
 
IR (KBr, vmax in cm
-1
) 
1630.52 (coumarinyl C=O), 1264.11 
(C=N),1140(C-OCH3), 1514.81 (C-O), 
808.992 (Aromatic C-H),756.923(C=C) 
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Figure 21: UV Spectrum of I4 
 
Figure 22: IR Spectrum of I4 
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Compound Code: I5 
O
O
OH
O
CH3
O
N
 
 
Chemical name 
3-[3-(3-hydroxy-4-methoxyphenyl)-
1,2-oxazol-5-yl]-2H-chromen-2-one 
 
 
UV Spectrum 
Solvent used: Methanol 
 
λmax : 276 
 
IR (KBr, vmax in cm
-1
) 
3064.33 (Aromatic C-H),1634.38 
(coumarinyl C=O), 1486.85 (C-
O),1231.33 (C=N),1140.69(C-
OCH3),719.318 (C-H bend) 
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Figure 23: UV Spectrum of I5 
 
Figure 24: IR Spectrum of I5 
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Compound Code: T1 
O O
N
N
H NH2
S
 
 
Chemical name 
3-(2-oxo-2H-chromen-3-yl)-5-phenyl-2,5-
dihydro-1H-pyrazole-1-carbothioamide 
 
 
UV Spectrum 
Solvent used: Methanol 
 
λmax : 276 
 
IR (KBr, vmax in cm
-1
) 
3436.53 (NH2), 3209.22 (C-NH), 1608.34 
(coumarinyl C=O), 1488.78(AromaticC=C), 
1384.64 (C=S), 1270.86 (C-N), 884.20(C-H 
bend) 
1
H NMR Spectral data 
δ 6.84 (s, 2H pyrazole ring),  δ 6.71, 6.88, (s, 
2H NH), δ 9.04 (s, 1H coumarin (CH)), δ 7.25-
8.02 (m, 9H ArH), 6.86 (s, 1H =CH) 
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Mass Spectral data 
Molecular weight of the compound: 341 
S/NO Fragments m/z values 
1 
O O
N
N
H NH2
S
+
 
341 
2 
O O
CH3
+
 
167 
3 
O O
+
 
147 
4 
N
NNH2
S
+
 
133 
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Figure 25: UV Spectrum of T1 
 
Figure 26: IR Spectrum of T1 
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Figure 27: Mass Spectrum of T1 
 
Figure 28: NMR Spectrum of T1 
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Compound Code: T2 
O O
NH N
NH2
S
Cl
 
 
Chemical name 
5-(2-chlorophenyl)-3-(2-oxo-3,4-dihydro-2H-
chromen-3-yl)-2,3-dihydro-1H-pyrazole-1-
carbothioamide 
 
UV Spectrum 
Solvent used: Methanol 
λmax : 275 
 
IR (KBr, vmax in cm
-1
) 
3450.03(NH2), 3334.32(C-NH), 
1625.7(coumarinylC=O),1176(C=S),1488.78 
(AromaticC=C),884.20(Aromatic C-H), 759.81(C-Cl) 
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Figure 29:  UV Spectrum of T2 
 
Figure 30: IR Spectrum of T2 
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Compound Code: T3 
O O
NN
SNH2
O2N
 
 
Chemical name 
5-(2-nitrophenyl)-3-(2-oxo-2H-chromen-3-yl)-4,5-
dihydro-1H-pyrazole-1-carbothioamide 
 
UV Spectrum 
Solvent used: Methanol 
λmax : 271 
 
IR (KBr, vmax in cm
-1
) 
3445.21(NH2),1636.3(coumarinylC=O), 
1524.45(C=N), 1470.46(C=S), 
1384.64(C-NO2) ,1350.89(C-N), 615.18(aromatic C-H)   
 
 
 
 
 
 
 
 
 
 
 
Figure 31: UV Spectrum of T3 
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Figure 32: IR Spectrum of T3 
 
Compound Code: T4 
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O
O N N
NH2
S
O CH3
O
CH3
 
Chemical name 
5-(3,4-dimethoxyphenyl)-3-(2-oxo-2H-chromen-3-
yl)-2,3-dihydro-1H-pyrazole-1-carbothioamide 
UV Spectrum Solvent used: Methanolλmax : 276 
IR (KBr, vmax in cm
-1
) 
3478.95(NH2),1605.45(coumarinylC=O), 
1509.99(C=N) ,1455.99(C-N), 
,1383.68(C=S),1195.65(C-OCH3), 
811.88(C-H) 
 
 
 
 
 
 
 
 
 
Figure 33: UV Spectrum of T4 
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Figure 34: IR Spectrum of T4 
 
Compound Code: T5 
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O
O N N
NH2
S
OH
O
CH3
 
 
Chemical name 
5-(3-hydroxy-4-methoxyphenyl)-3-(2-oxo-2H-
chromen-3-yl)-2,3-dihydro-1H-pyrazole-1-
carbothioamide 
 
UV Spectrum 
Solvent used: Methanol 
λmax : 276 
 
IR (KBr, vmax in cm
-1
) 
3353.6(NH2),3379.64(AromaticC-H), 
1607.38(coumarinylC=O), 1487.81(C=N),1455.03(C-
N), 1383.68(C=S),1101.15(C-OCH3) 
 
 
 
 
 
 
 
 
 
 
Figure 35: UV Spectrum of T5 
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Figure 36: IR Spectrum of T5 
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ENZYME INHIBITION STUDIES 
DRUGS AND CHEMICALS 
 Acarbose (Bicon Ltd, Banglore), porcine pancreatic α-amylase (Sigma-
Aldrich, USA), Glucose assay kits (Agappe Diagnostics, Kerala) 3, 5-dinitro 
salicyclic acid (HiMedia, Mumbai) and potato starch and maltose 
(Lobachemie,Mumbai) were purchased for the study. All the other chemicals used 
in the study were of analytical grade and were of commercial grade and obtained 
from respective manufacturers.  
IN VITRO ANTIDIABETIC STUDIES 
 In vitro anti-diabetic potential of the synthesized coumarin derivatives 
were studied by performing the enzyme inhibition assay using carbohydrate 
digestive enzymes i.e., α-amylase. 
IN VITRO INHIBITION OF α- AMYLASE 
 The study was carried out with porcine pancreatic α-amylase with starch as 
substrate. Acarbose was selected as the standard drug for comparison of results 
and coumarin derivatives dissolved in water.  
PRINCIPLE
[120]
 
 α-amylase digests the starch in reaction mixture to yield maltose. The 
maltose produced would reduce the 3, 5-dinitrosalicyclic acid in the colouring 
agent to 3 amino 5-nitrosalicyclicacid. The reaction mixture produced a colour 
change from orange to red. The intensity of red colour will be directly 
proportional to the amount of maltose produced. When an enzyme inhibitor is 
present in reaction mixture digestion of starch, production of maltose and intensity 
of red colour produced will be less.  
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PREPARATION OF REAGENTS
[121]
 
Preparation of Phosphate Buffer 
 Phosphate buffer (20 mM) of pH 6.9 (prepared with sodium phosphate 
monobasic and sodium chloride). 
 
Preparation of Starch Solution 
 Starch solution (1.0%) prepared with phosphate buffer by boiling. 
Preparation of Coloring Reagents 
 Colouring reagent is prepared by slowly adding sodium potassium tartarate 
solution [prepared in the ratio 12 g of solid dissolved in 8 ml of 2M sodium 
hydroxide] to 20 ml of 96 mM 3,5-dinitrosalicyclic acid (prepared in distilled 
water) and then diluting the mixture to 40 ml with distilled water. 
Preparation of enzyme solution 
 Enzyme solution, alpha amylase (0.5 mg/ml) prepared with phosphate 
buffer pH 6.9. 
PROCEDURE
[122-124]
 
 From 1 mg/ml stock solution different concentration (5-500 µg/ml) of 
coumarin derivatives were prepared by adding few drops of dimethylsulfoxide and 
volume made up with water. About 500 µl of α-amylase (0.5 mg/ml) was added 
and was incubated for 10 minutes at room temperature. Then added 500µl of 1.0% 
starch solution and incubated for another 10 minutes. After that 1 ml of the 
coloring reagent was added to the reaction mixture and heated in a boiling water 
bath for 5 minutes. After cooling, 10 ml of distilled water was added for dilution. 
To measure the absorbance of the colored extracts, blank was prepared for each 
set of concentration of test sample by replacing the enzyme solution with buffer. 
Control incubations representing 100% enzyme activity was prepared by replacing 
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the test drug with water. The absorbance was then measured at 540 nm. The α- 
amylase inhibition was expressed as percentage of inhibition and the IC50 values 
determined by linear regression plots with varying concentration of synthesized 
coumarin against percentage inhibition. 
CALCULATION OF PERCENTAGE OF INHIBITION:      
 PERCENTAGE INHIBITION = (
   
 
    ) 
STATISTICAL ANALYSIS 
 All the analyses were carried out in triplicates and the results were 
expressed in mean± SD.  
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RESULT AND DISCUSSION  
Evaluation of α-amylase inhibitory activity  
 All the newly designed and synthesised compounds were screened for in 
vitro α-amylase inhibitory activity at 5, 10, 25, 50, 100, 200, 400, 500μg/ml 
concentration. Acarbose was used as the standard drug in the same concentration. 
A graded increase in the percentage of inhibition was observed with increase in 
concentration. In this study Ten compounds were synthesised in that 5 compounds 
belongs to Isoxazole derivatives in which IC50 of compound-I4(28 μg/ml) and  
other 5 compounds belongs to Pyrazole derivatives in which IC50 of compounds-
T2 (35 μg/ml ) and T3(25 μg/ml) showed percentage of inhibition closer to that of 
standard(Acarbose-12 μg/ml). The IC50 values of synthesised compounds were 
found by plotting a graph of percentage inhibition verus concentration in μg/ml. 
The values were compared with that of standard. 
 Among I1-5 series of isoxazoles derivatives of coumarin, I4 showed good 
percentage of inhibition at all concentration (5 μg/ml-500 μg). The IC50 values for 
these compounds were found to be 28 μg/ml respectively which is close to IC50 
value of acarbose (10 μg/ml). I1 and I5 showed moderate α-amylase inhibitory 
activity at all concentrations. The IC50 value for this compound found to be  
49 μg/ml and 50 μg/ml. Other compounds I2 and I3 exhibited the least α-amylase 
inhibitory activity at all concentrations with  IC50 values 210 μg/ml and 110 μg/ml  
respectively. 
 Among T1-5 series of pyrazoles derivatives of coumarin, T1 and T3 showed 
good percentage of inhibition at all concentration (5 μg/ml-500 μg/ml). The IC50 
values for these compounds were found to be 24 μg/ml and 25 μg/ml respectively 
which is close to IC50 value of acarbose (25 μg/ml). T2 showed moderate  
α-amylase inhibitory activity at all concentrations. The IC50 value for this 
compound found to be 35 μg/ml. Other compounds T4 and T5 exhibited the least 
α-amylase inhibitory activity at all concentrations with  IC50 values 75 μg/ml and 
150 μg/ml  respectively. 
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PERCENTAGE OF α-AMYLASE INHIBITORY POTENTIAL OF 
SYNTHESISED COUMARIN DERIVATIVES 
TABLE 5: IN VITRO α-AMYLASE INHIBITORY ACTIVITY 
Compound 
code 
5 
μg/ml 
10 
μg/ml 
25 
μg/ml 
50 
μg/ml 
100 
μg/ml 
200 
μg/ml 
400 
μg/ml 
500 
μg/ml 
IC50 μg/ml 
I1 30.69 40.46 42.79 51.16 57.67 60.46 71.16 79.06 49 
I2 9.01 16.86 22.13 31.96 39.89 48.23 59.20 67.20 210 
I3 19.16 28.83 35.75 42.75 49.85 58.75 73.58 79.00 110  
I4 29.16 35.16 44.83 56.25 64.16 67.33 78.75 81.58 28  
I5 29.41 36.37 40.47 51.37 59.70 65.37 75.64 79.60 50  
T1 34.00 42.50 55.30 61.00 64.00 71.00 79.00 82.03 24  
T2 24.54 35.00 46.81 49.09 65.00 75.00 85.00 88.00 35  
T3 33.75 41.25 54.50 60.41 68.75 77.50 80.16 85.40 25  
T4 19.58 32.91 37.30 45.33 54.66 65.50 76.25 79.50 75  
T5 21.96 27.84 30.98 40.39 46.60 52.54 56.47 66.80 150  
Standard 
(Acarbose) 
27.28 46.17 52.05 63.34 73.11 79.24 82.21 94.01 12 
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SUMMARY AND CONCLUSION 
 
SUMMARY  
 The present work was focused on the designing and synthesis of novel 
isoxazole and pyrazole derivatives incorporated with coumarin moiety having α-
amylase enzyme inhibitory activity. For this, following approach has been 
adopted.  
 
PHASE I: LITERATURE REVIEW  
 Literature survey showed that coumarin is a drug like scaffold and is a 
core skeleton for the active sites involved in enzyme inhibiton in Type 2 diabetes. 
It also revealed that isoxazole, pyrazole posses enzyme inhibition for Type 2 
diabetes. 
 
PHASE II: DRUG DESIGN APPROACH  
 It involves the following stages:  
 
Stage 1: Identification of target  
 α-amylase was selected as the target enzyme as its inhibition will prevent 
carbohydrate hydrolysis. The target enzyme (1UA7) was downloaded from RCBs 
Protein Databank. 
 
Stage 2: Virtual screening 
 Virtual screening was done by iGEMDOCK v.2 software. More than 500 
compounds from the pubchem and zinc database were screened from which 50 
lead compounds were selected. From this, based on the bioactivity score, 
Coumarin was selected as the lead molecule 
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Stage 3: Lead optimization 
 Lead optimisation was done by computation of drug likness score. 
Isoxazole and Pyrazole derivatives of coumarin were the desired compounds with 
good molecular properties and bioactivity score, ie., the compounds I1-5 and T1-5, 
showed good scores. 
 
PHASE III: SYNTHESIS AND PHYSICAL CHARACTERIZATION  
A)  Synthesis of the designed compounds  
 In this work, ten new compounds were synthesized in which five different 
isoxazole and five different pyrazole derivatives with coumarin moiety.  The first 
step involved the synthesis of 3- acetyl coumarin by Knovenagel reaction. 
Chalcones were prepared from 3- acetyl coumarin and different aromatic 
aldehydes. Finally, the chalcones were reacted with hydroxylamine hydrochloride 
and thiosemicarbazide  to form isoxazoles and pyrazoles.  
 
B)  Physical characterization  
 Melting point of all the newly synthesised compounds was determined by 
capillary tube method. Rf values were determined by fixing various suitable 
solvent system on precoated silicagel- G plates. 
 
PHASE IV: SPECTRAL STUDIES 
  The structure of the synthesised compounds was established by using UV, 
IR, 
1
H NMR, and Mass spectral data. 
 
PHASE V: EVALUATION OF BIOLOGICAL ACTIVITIES 
Evaluation of α-amylase inhibitory activity 
 All the newly sysnthesised compounds were screened for in vitro α-
amylase inhibitory activity. All compounds showed significant activity in 
inhibition of the α-amylase enzyme. Comparatively I4, T1 and T3 showed good % 
of inhibition activity at lower concentrations (20-50μg/ml), while I1, I5, T2, T4 
showed moderate activity. (50-200μg/ml) 
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CONCLUSION 
 The present study establishes that computational tools help in minimizing 
the tedious process of drug discovery and delivers new drug candidate 
more quickly.  
 α-amylase enzyme was selected as target and virtual screening made 
selection of lead compounds easier and coumarin was selected as lead 
molecule. 
 The drug likeness score established the compounds to be 
 pharmacokinetically active. 
 The proposed ten compounds of isoxazole and pyrazole derivatives with 
coumarin ring system were synthesised in good yield using the developed 
schemes. 
 All the reactions were monitored by TLC one spot technique and the 
structures of the synthesised compounds were confirmed by UV, IR, 
1
H 
NMR, Mass spectra. 
 Compounds I4, T1 and T3 exhibited maximum α-amylase inhibitory 
activity. 
 Among the synthesized compounds, I4 and T1 can be taken for further 
studies as the lead molecule and acute toxicity studies are to be done on 
these promising compounds.  
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Structure of Lead Molecules identified 
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LIST OF NEWLY SYNTHESIZED COMPOUND 
SUBSTITUTED ISOXAZOLE DERIVATIVES 
Compound 
code 
IUPAC name Structure 
I1 
3-(3-phenyl-2,3-
dihydro-1,2-
oxazol-5-yl)-2H-
chromen-2-one 
O O
NH
O
 
I2 
3-[3-(2-
chlorophenyl)-2,3-
dihydro-1,2-
oxazol-5-yl]-2H-
chromen-2-one O O
O N
H Cl
 
I3 
3-[3-(2-
nitrophenyl)-4,5-
dihydro-1,2-
oxazol-5-yl]-2H-
chromen-2-one O O
O N
H
O2N
 
I4 
3-[3-(3,4-
dimethoxyphenyl)-
2,5-dihydro-1,2-
oxazol-5-yl]-2H-
chromen-2-one 
O
O
O
CH3
O
CH3
O
N
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Compound 
code 
IUPAC name Structure 
I5 
3-[3-(3-hydroxy-4-
methoxyphenyl)-
1,2-oxazol-5-yl]-
2H-chromen-2-one 
 
O
O
OH
O
CH3
O
N
 
 
  
List of Newly Synthesized Compounds 
 
 
 
 
 
Department of Pharmaceutical Chemistry 141 
SUBSTITUTED PYRAZOLE DERIVATIVES 
Compond 
code 
IUPAC name Structure 
T1 
3-(2-oxo-2H-
chromen-3-yl)-5-
phenyl-2,5-
dihydro-1H-
pyrazole-1-
carbothioamide 
 
O O
N
N
H NH2
S
 
T2 
5-(2-
chlorophenyl)-3-
(2-oxo-3,4-
dihydro-2H-
chromen-3-yl)-
2,3-dihydro-1H-
pyrazole-1-
carbothioamide O O
NH N
NH2
S
Cl
 
T3 
5-(2-nitrophenyl)-
3-(2-oxo-2H-
chromen-3-yl)-
4,5-dihydro-1H-
pyrazole-1-
carbothioamide 
O O
NN
SNH2
O2N
 
T4 
5-(3,4-
dimethoxyphenyl)-
3-(2-oxo-2H-
chromen-3-yl)-
2,3-dihydro-1H-
pyrazole-1-
carbothioamide 
O
O N N
NH2
S
O CH3
O
CH3
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Compond 
code 
IUPAC name Structure 
T5 
5-(3-hydroxy-4-
methoxyphenyl)-
3-(2-oxo-2H-
chromen-3-yl)-
2,3-dihydro-1H-
pyrazole-1-
carbothioamide 
O
O N N
NH2
S
OH
O
CH3
 
 
